A malignant tumor arising from the epithelium of the BILE DUCTS.
Tumors or cancer of the BILE DUCTS.
Passages within the liver for the conveyance of bile. Includes right and left hepatic ducts even though these may join outside the liver to form the common hepatic duct.
A benign tumor of the intrahepatic bile ducts.
Adenocarcinoma of the common hepatic duct bifurcation. These tumors are generally small, sharply localized, and seldom metastasizing. G. Klatskin's original review of 13 cases was published in 1965. Once thought to be relatively uncommon, tumors of the bifurcation of the bile duct now appear to comprise more than one-half of all bile duct cancers. (From Holland et al., Cancer Medicine, 3d ed, p1457)
Passages external to the liver for the conveyance of bile. These include the COMMON BILE DUCT and the common hepatic duct (HEPATIC DUCT, COMMON).
A genus of trematode liver flukes of the family Opisthorchidae. It consists of the following species: O. felineus, O. noverca (Amphimerus noverca), and O. viverrini. The intermediate hosts are snails, fish, and AMPHIBIANS.
Infection with flukes of the genus Opisthorchis.
Any surgical procedure performed on the biliary tract.
Predominantly extrahepatic bile duct which is formed by the junction of the right and left hepatic ducts, which are predominantly intrahepatic, and, in turn, joins the cystic duct to form the common bile duct.
Chronic inflammatory disease of the BILIARY TRACT. It is characterized by fibrosis and hardening of the intrahepatic and extrahepatic biliary ductal systems leading to bile duct strictures, CHOLESTASIS, and eventual BILIARY CIRRHOSIS.
Tumors or cancer of the LIVER.
Excision of all or part of the liver. (Dorland, 28th ed)
A condition characterized by the formation of CALCULI and concretions in the hollow organs or ducts of the body. They occur most often in the gallbladder, kidney, and lower urinary tract.
Infection of the biliary passages with CLONORCHIS SINENSIS, also called Opisthorchis sinensis. It may lead to inflammation of the biliary tract, proliferation of biliary epithelium, progressive portal fibrosis, and sometimes bile duct carcinoma. Extension to the liver may lead to fatty changes and cirrhosis. (From Dorland, 27th ed)
Liver disease caused by infections with parasitic flukes of the genus FASCIOLA, such as FASCIOLA HEPATICA.
The channels that collect and transport the bile secretion from the BILE CANALICULI, the smallest branch of the BILIARY TRACT in the LIVER, through the bile ductules, the bile ducts out the liver, and to the GALLBLADDER for storage.
A species of helminth commonly called the sheep liver fluke. It occurs in the biliary passages, liver, and gallbladder during various stages of development. Snails and aquatic vegetation are the intermediate hosts. Occasionally seen in man, it is most common in sheep and cattle.
A species of trematode flukes of the family Opisthorchidae. Many authorities consider this genus belonging to Opisthorchis. It is common in China and other Asiatic countries. Snails and fish are the intermediate hosts.
Formerly known as Siam, this is a Southeast Asian nation at the center of the Indochina peninsula. Bangkok is the capital city.
Fiberoptic endoscopy designed for duodenal observation and cannulation of VATER'S AMPULLA, in order to visualize the pancreatic and biliary duct system by retrograde injection of contrast media. Endoscopic (Vater) papillotomy (SPHINCTEROTOMY, ENDOSCOPIC) may be performed during this procedure.
Tumors or cancer of the gallbladder.
Jaundice, the condition with yellowish staining of the skin and mucous membranes, that is due to impaired BILE flow in the BILIARY TRACT, such as INTRAHEPATIC CHOLESTASIS, or EXTRAHEPATIC CHOLESTASIS.
Inflammation of the biliary ductal system (BILE DUCTS); intrahepatic, extrahepatic, or both.
Tumors or cancer in the BILIARY TRACT including the BILE DUCTS and the GALLBLADDER.
A cell line derived from cultured tumor cells.
Sialylated Lewis blood group carbohydrate antigen found in many adenocarcinomas of the digestive tract, especially pancreatic tumors.
The removal of fluids or discharges from the body, such as from a wound, sore, or cavity.
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.
Non-invasive diagnostic technique for visualizing the PANCREATIC DUCTS and BILE DUCTS without the use of injected CONTRAST MEDIA or x-ray. MRI scans provide excellent sensitivity for duct dilatation, biliary stricture, and intraductal abnormalities.
A crystalline compound used as a laboratory reagent in place of HYDROGEN SULFIDE. It is a potent hepatocarcinogen.
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
Unstable isotopes of iridium that decay or disintegrate emitting radiation. Ir atoms with atomic weights 182-190, 192, and 194-198 are radioactive iridium isotopes.
An imaging test of the BILIARY TRACT in which a contrast dye (RADIOPAQUE MEDIA) is injected into the BILE DUCT and x-ray pictures are taken.
The presence of parasites in food and food products. For the presence of bacteria, viruses, and fungi in food, FOOD MICROBIOLOGY is available.
The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.
Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.
A congenital anatomic malformation of a bile duct, including cystic dilatation of the extrahepatic bile duct or the large intrahepatic bile duct. Classification is based on the site and type of dilatation. Type I is most common.
A short thick vein formed by union of the superior mesenteric vein and the splenic vein.
The transference of a part of or an entire liver from one human or animal to another.
Ability of neoplasms to infiltrate and actively destroy surrounding tissue.
All of the processes involved in increasing CELL NUMBER including CELL DIVISION.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Presence or formation of GALLSTONES in the BILIARY TRACT, usually in the gallbladder (CHOLECYSTOLITHIASIS) or the common bile duct (CHOLEDOCHOLITHIASIS).
The largest bile duct. It is formed by the junction of the CYSTIC DUCT and the COMMON HEPATIC DUCT.
Surgical formation of an opening (stoma) into the COMMON BILE DUCT for drainage or for direct communication with a site in the small intestine, primarily the DUODENUM or JEJUNUM.
A Y-shaped surgical anastomosis of any part of the digestive system which includes the small intestine as the eventual drainage site.
Surgical union or shunt between ducts, tubes or vessels. It may be end-to-end, end-to-side, side-to-end, or side-to-side.
The terms, expressions, designations, or symbols used in a particular science, discipline, or specialized subject area.
Diseases of the GALLBLADDER. They generally involve the impairment of BILE flow, GALLSTONES in the BILIARY TRACT, infections, neoplasms, or other diseases.
A storage reservoir for BILE secretion. Gallbladder allows the delivery of bile acids at a high concentration and in a controlled manner, via the CYSTIC DUCT to the DUODENUM, for degradation of dietary lipid.
Tomography using x-ray transmission and a computer algorithm to reconstruct the image.
A clinical manifestation of HYPERBILIRUBINEMIA, characterized by the yellowish staining of the SKIN; MUCOUS MEMBRANE; and SCLERA. Clinical jaundice usually is a sign of LIVER dysfunction.

Lobar decrease in 99mTc-GSA accumulation in hilar cholangiocarcinoma. (1/1040)

Hilar cholangiocarcinoma can obstruct hepatic ducts and involve the portal veins. Both biliary stasis and decrease in portal venous flow are known to reduce 99mTc-diethylenetriamine pentaacetic acid-galactosyl human serum albumin (GSA) accumulation. The specific relationship between these pathological conditions due to hilar cholangiocarcinomas and 99mTc-GSA accumulation has never been clarified. METHODS: Sixteen patients with hilar cholangiocarcinomas who underwent 99mTc-GSA liver scintigraphy were reviewed. The relationship between significant decrease in 99mTc-GSA accumulation and lobar biliary stasis, or decrease in the portal venous flow, was evaluated. Average counts of region of interest placed in both right and left lobes were compared in the same transaxial SPECT section. Count ratios of right and left lobes were calculated. RESULTS: Significant lobar decrease in 99mTc-GSA accumulation was observed in 6 of the 16 patients. Ipsilateral portal venous stenosis or obstruction was seen in all these 6 patients, whereas ipsilateral portal venous stenosis or obstruction was seen in only 1 of the other 10 patients. Symmetric bile duct dilatation was seen in 13 patients, and asymmetric bile duct dilatation was seen in 3. Lobar decrease in 99mTc-GSA accumulation correlated well with decrease in ipsilateral portal venous flow (P < 0.0005). The count ratio was significantly reduced when unilateral portal venous flow decreased (P < 0.05). CONCLUSION: Using 99mTc-GSA liver scintigraphy, we can predict lobar decrease in ipsilateral portal venous flow and monitor hepatic functional lateralities in patients with hilar cholangiocarcinomas.  (+info)

Binding of tumour necrosis factor-alpha (TNF-alpha) to TNF-RI induces caspase(s)-dependent apoptosis in human cholangiocarcinoma cell lines. (2/1040)

Cholangiocarcinoma (CCA), a tumour of the bile duct epithelium, occurs with a higher incidence in South-east Asian countries than in Europe and North America. The prognosis is poor, due to the unavailability of early diagnosis and the tumours being relatively resistant to chemotherapy. In the present study one of the fatal routes of this tumour was studied. This death was stimulated by TNF-alpha. TNF-alpha at a concentration of 760 pg/ml and 100 pg/ml in the presence of 1 microgram/ml actinomycin D induced 50% cell death of the two established human cholangiocarcinoma cell lines HuCCA-1 and HuCCA-INu, respectively. Preincubation of both cell lines with MoAb to TNF-RI or TNF-RII before TNF-alpha treatment showed that only the MoAb specific to TNF-RI inhibited death. The death of these two cell lines was proved to be apoptosis. Western blot analysis of extracts from both cell lines demonstrated a cleavage of poly (ADP-ribose) polymerase (PARP) within 6-8 h following TNF-alpha treatment. The degradation of PARP was prevented by a MoAb to TNF-RI indicating that the TNF-RI but not TNF-RII was involved in TNF-induced apoptosis in these two human cholangiocarcinoma cell lines. Moreover, peptide inhibitor for caspase II subfamily, Ac-DEVD-CHO, reduced the cytolysis of TNF-alpha-treated cholangiocarcinoma cells. The inhibitor also prevented degradation of PARP. These results indicate that the interaction between TNF-alpha and TNF-RI alone generated a sufficient signal to activate a caspase II subfamily-dependent apoptosis in human cholangiocarcinoma cell lines.  (+info)

Lymph node metastasis in intrahepatic cholangiocarcinoma. (3/1040)

BACKGROUND: Lymph node metastasis is a significant prognostic factor in intrahepatic cholangiocarcinoma. This study was aimed at investigating lymph node metastasis in intrahepatic cholangiocarcinoma and to examine whether the extent of metastasis affects outcomes after surgery. METHODS: From 1980 through 1996, 70 patients with intrahepatic cholangiocarcinoma underwent hepatectomy, with a 50% curative resection rate. Lymph node dissection was performed in 51 patients, and the presence of lymph node metastasis was examined microscopically. The metastatic nodes were divided into groups N1, N2 or N3 using the classification proposed by the Liver Cancer Study Group of Japan. RESULTS: Twenty-three patients had lymph node metastasis. Metastasis was to N1 nodes in 10 patients, to N2 nodes in nine patients and to N3 nodes in four patients. Nineteen patients had metastatic nodes in the hepatoduodenal ligament, which was the most common metastatic site regardless of tumor location. The five-year survival rate in patients with lymph node metastasis (0%) was significantly lower (p < 0.0001) than that in patients without lymph node metastasis (51 %); however, five-year survival rates did not differ between patients with metastases to N1, N2 and N3 nodes. CONCLUSIONS: Lymph nodes in the hepatoduodenal ligament may be sentinel nodes for intrahepatic cholangiocarcinoma, and outcomes after surgery for patients with lymph node metastasis are poor regardless of the sites of nodal metastasis.  (+info)

Promoting effects of 3-chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-furanone on rat glandular stomach carcinogenesis initiated with N-methyl-N'-nitro-N-nitrosoguanidine. (4/1040)

The modifying effects of 3-chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-furanone (MX), a mutagenic by-product in chlorinated water, on the development of glandular stomach cancers were investigated in Wistar rats. A total of 120 males, 6 weeks of age, were divided into six groups. After initiation with 100 ppm N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) solution and 5% NaCl diet for 8 weeks, 30 rats each in groups 1-3 were given MX in the drinking water at concentrations of 30, 10, or 0 ppm for the following 57 weeks. Ten animals each in groups 4-6 were administered the MX without prior carcinogen exposure. There were no statistical significant differences in final body weights between the groups. The incidences and multiplicities of adenocarcinomas in the glandular stomachs were significantly higher (P < 0.05) in the initiated 30 ppm MX group than those in the MNNG/NaCl group. The incidences of atypical hyperplasias in the glandular stomachs were also significantly increased (P < 0.05 or 0.01) by the MX treatments. With their multiplicity, the effects were clearly dose dependent. Interestingly, the 30 ppm MX alone itself induced atypical hyperplasias in the pylorus, although the incidences and severity were low. Moreover, MX showed a tendency to enhance the development of intrahepatic cholangiocellular tumors and thyroid follicular cell tumors in the MNNG-treated animals. The results of the present study thus indicate that MX exerts promoting effects when given during the postinitiation phase of two-stage glandular stomach carcinogenesis in rats.  (+info)

Expression of p73, a novel protein related to the p53 tumour suppressor p53, and apoptosis in cholangiocellular carcinoma of the liver. (5/1040)

p73, the first homologue of the tumour suppressor protein p53, was recently discovered on chromosome 1p36 and has been shown to induce apoptosis in a p53-like manner. The present study was performed with the aim of investigating the expression of p53, its new homologue p73 and the occurrence of apoptosis in cholangiocellular carcinoma. Protein levels of p73 were examined in 41 patients with curatively (R0-) resected cholangiocellular carcinomas with an antiserum, raised against a peptide in the N-terminal domain of p73. The incidence of mutations in the p53 gene was analysed by direct sequencing and also immunohistochemically. Apoptotic cell death was assessed using in-situ end-labelling (ISEL) technique in combination with morphological criteria. The results obtained were correlated with patient survival. Immunostaining of p73 protein was detected in 17/41 carcinomas examined (41%). The immunoreactivity was confined to the cell nucleus. In 15/41 patients (37%), mutations of the p53 gene were observed. Eleven out of these 15 patients stained also positive for p73. In contrast, out of 26 patients without any detectable p53 mutation, only six exhibited p73 immunostaining. We failed to observe a correlation between p73 expression or p53 and apoptosis within a given tumour. Survival analysis including the parameters stage and grade of disease, p73 and p53, and also apoptosis, showed that tumour stage and grade as well as p53 and p73 were significantly related to prognosis. In Cox regression survival analysis, however, only extent of primary tumour and lymph node status had an independent prognostic impact. Our results with a high prevalence of p73 within tumours harbouring mutated p53 gene suggest that p73 could compensate for p53 function. We failed to establish p73 or p53 as independent prognostic factors in cholangiocellular carcinoma of the liver.  (+info)

Intrahepatic peripheral cholangiocarcinoma: CT features in 18 pathologically proven cases. (6/1040)

OBJECTIVE: To determine the morphological features of 18 pathologically proven intrahepatic peripheral cholangiocarcinoma (IHPCC) cases in computerized tomography (CT) image. METHODS: All 18 patients had CT, using Picker I.Q.T/C and taking pre-contrast continuous 10-mm sections throughout the liver and post-contrast continuous 10-mm sections throughout the focuses. RESULTS: The disease was characterized in CT image by the following: all focuses were found in the periphery of the liver and shown as a lobulated or fused hypodense space-occupying mass; there were one or more divergent or confluent, circular or irregular cystic areas with much lower density, in the majority. All focuses could be enhanced slightly and most revealed a dim edge. Dilated bile ducts around the focus were found frequently; the dilated bile ducts especially seemed to encircle the focus (33.3%, 6/18). This phenomenon were referred to as "encysted sign of dilated bile ducts". CONCLUSIONS: CT scanning should be one of the most important investigative methods for IHPCC due to the disease characteristics identified in CT image, especially "encysted sign of dilated bile ducts" which possesses specificity in diagnosing the disease.  (+info)

Apoptosis and tumorigenesis in human cholangiocarcinoma cells. Involvement of Fas/APO-1 (CD95) and calmodulin. (7/1040)

We have previously demonstrated that tamoxifen inhibits the growth of human cholangiocarcinoma cells in culture and inhibits tumor growth when cells are injected into nude mice. However, the mechanism of action of tamoxifen remains unknown. Here we demonstrate that tamoxifen and trifluoperazine, both potent calmodulin antagonists, induce apoptosis in vitro, probably acting via the Fas system, in human cholangiocarcinoma cells. Human cholangiocarcinoma cell lines heterogeneously express Fas antigen on their surface. Fas-negative and Fas-positive surface-expressing cells were isolated, cloned, and cultured. Fas antibody, tamoxifen, and trifluoperazine induced dose-dependent apoptosis only in Fas-positive cells; Fas-negative cells were unaffected. Furthermore, apoptosis induced by tamoxifen in Fas-positive cells was blocked by an inhibitory Fas antibody. Tamoxifen was not acting through an anti-estrogenic mechanism, because neither Fas-negative nor Fas-positive cells expressed estrogen receptors and the pure anti-estrogen compound, ICI 182780, did not induce apoptosis in either cell line. Fas-negative cells, but not Fas-positive cells, were able to produce tumors when subcutaneously injected into nude mice. These findings suggest Fas may be a candidate oncogene involved in the pathogenesis of cholangiocarcinoma. Furthermore, the similarity between the pro-apoptotic effects of tamoxifen and trifluoperazine support an underlying molecular mechanism for Fas-mediated apoptosis that involves calmodulin.  (+info)

Recurrent thrombo-embolic episodes: the association of cholangiocarcinoma with antiphospholipid syndrome. (8/1040)

Antiphospholipid syndrome is a disorder of recurrent vascular thrombosis, pregnancy loss and thrombocytopenia associated with persistently elevated levels of antiphospholipid antibodies. It was first described in a group of patients with systemic lupus erythematosus but has since been associated with a wide range of conditions, including other autoimmune disorders and malignancy. It can also occur in isolation, the so-called primary antiphospholipid syndrome. We describe an elderly woman with the antiphospholipid syndrome thought to be associated with a cholangiocarcinoma.  (+info)

TY - JOUR. T1 - Neuropeptide Y inhibits cholangiocarcinoma cell growth and invasion. AU - DeMorrow, Sharon. AU - Onori, Paolo. AU - Venter, Julie. AU - Invernizzi, Pietro. AU - Frampton, Gabriel. AU - White, Mellanie. AU - Franchitto, Antonio. AU - Kopriva, Shelley. AU - Bernuzzi, Francesca. AU - Francis, Heather. AU - Coufal, Monique. AU - Glaser, Shannon. AU - Fava, Giammarco. AU - Meng, Fanyin. AU - Alvaro, Domenico. AU - Carpino, Guido. AU - Gaudio, Eugenio. AU - Alpini, Gianfranco. PY - 2011/5. Y1 - 2011/5. N2 - No information exists on the role of neuropeptide Y (NPY) in cholangiocarcinoma growth. Therefore, we evaluated the expression and secretion of NPY and its subsequent effects on cholangiocarcinoma growth and invasion. Cholangiocarcinoma cell lines and nonmalignant cholangiocytes were used to assess NPY mRNA expression and protein secretion. NPY expression was assessed by immunohistochemistry in human liver biopsies. Cell proliferation and migration were evaluated in vitro by MTS ...
TY - JOUR. T1 - Combined hepatocellular carcinoma and intrahepatic cholangiocarcinoma. T2 - Outcome after liver transplantation. AU - Maganty, Kishore. AU - Levi, David. AU - Moon, Jang. AU - Bejarano, Pablo A.. AU - Arosemena, Leopoldo. AU - Tzakis, Andreas. AU - Martin, Paul. PY - 2010/12/1. Y1 - 2010/12/1. N2 - Background: Combined hepatocellular carcinoma and intrahepatic cholangiocarcinoma is a rare hepatobiliary malignancy incorporating components derived from both hepatocyte and intrahepatic bile duct epithelium. The natural history, treatment, and prognosis of this distinct cancer differ from hepatocellular carcinoma (HCC) or cholangiocarcinoma (CC) and are not completely understood. There is considerable controversy about the classification, treatment, and survival, which in turn is related to the rarity of the condition. Treatment options include surgical resection and the prognosis is believed to be better than CC but worse than HCC alone. Methods: We report a single-center liver ...
TY - JOUR. T1 - Histopathological characteristics of hypervascular cholangiocellular carcinoma as an early stage of cholangiocellular carcinoma. AU - Sato, Yuya. AU - Ojima, Hidenori. AU - Onaya, Hiroaki. AU - Mori, Taisuke. AU - Hiraoka, Nobuyoshi. AU - Kishi, Yoji. AU - Nara, Satoshi. AU - Esaki, Minoru. AU - Shimada, Kazuaki. AU - Kosuge, Tomoo. AU - Sugihara, Kenich. AU - Kanai, Yae. PY - 2014/10/1. Y1 - 2014/10/1. N2 - Aim: Prognosis of hypervascular cholangiocellular carcinoma (h-CCC) is reportedly better than that of ordinary hypovascular CCC (o-CCC). The aim of this study is to clarify the histopathological characteristics of h-CCC. Methods: On the basis of the findings in the arterial phase of contrast-enhanced computed tomography, 16 cases of mass-forming-type CCC were divided into two groups (h-CCC, n=8; o-CCC, n=8). Areas of high (Area H-a) and low (Area H-b) attenuation in h-CCC cases and areas of low attenuation in o-CCC cases (Area O) were delineated. These areas were then ...
The original observations of this study relate to inflammation, NO production, DNA damage, and inhibition of DNA repair as related mechanisms for the development and/or progression of cholangiocarcinoma. Our results directly demonstrate the following: (a) human cholangiocarcinomas express the iNOS protein; (b) proinflammatory cytokines stimulate iNOS message and protein expression and the production of NO in cholangiocarcinoma cell lines; (c) the magnitude of NO produced is sufficient to cause single-stranded, double-stranded, and oxidative DNA lesions in the malignant cell lines; and (d) stimulated NO generation is associated with impaired global DNA repair activity in the cholangiocarcinoma cell lines. These data suggest that NO generated in response to inflammation may initiate malignant transformation of biliary epithelia and/or promote progression of established cholangiocarcinoma. Each of these observations is discussed in greater detail below.. iNOS expression with NO generation has been ...
Slug is an E-cadherin repressor and a suppressor of PUMA (p53 upregulated modulator of apoptosis) and it has recently been demonstrated that Slug plays an important role in controlling apoptosis. In this study, we examined whether Slugs ability to silence expression suppresses the growth of cholangiocarcinoma cells and/or sensitizes cholangiocarcinoma cells to chemotherapeutic agents through induction of apoptosis. We targeted the Slug gene using siRNA (Slug siRNA) via full Slug cDNA plasmid (Slug cDNA) transfection of cholangiocarcinoma cells. Slug siRNA, cisplatin, or Slug siRNA in combination with cisplatin, were used to treat cholangiocarcinoma cells in vitro. Western blot was used to detect the expression of Slug, PUMA, and E-cadherin protein. TUNEL, Annexin V Staining, and cell cycle analysis were used to detect apoptosis. A nude mice subcutaneous xenograft model of QBC939 cells was used to assess the effect of Slug silencing and/or cisplatin on tumor growth. Immunohistochemical staining was used
Lymphoepithelioma-like carcinoma (LELC) of the liver is extremely rare. To our knowledge, only 16 cases of pure LELC or LELC with ordinary adenocarcinoma arising in the hepatobiliary tract have been reported in the English literature.1-7 Most of these tumours (68%, 11/16) were positive for Epstein-Barr virus (EBV) by EBV-encoded small non-polyadenylated RNA (EBER-1) in situ hybridisation.1-6 However, association of intrahepatic cholangiocarcinoma bearing an intense lymphoplasmacytic infiltration with EBV infection has not been reported. We were the first to present two cases of intrahepatic cholangiocarcinoma with dense lymphoplasmacytic infiltration from Southern China, an area that is well known for and has a high-incidence of nasopharyngeal carcinoma, showing EBV infection, but one case of LELC was associated with EBV infection as well. ...
Conditions: Adenocarcinoma; Adenocystic Carcinoma; Anal Cancer; Appendix Cancer; Brain Tumor; Glioblastoma; Astrocytoma; Bile Duct Cancer; Cholangiocarcinoma; Bladder Cancer; Bone Cancer; Synovial Sarcoma; Chondrosarcoma; Liposarcoma; Sarcoma, Kaposi; Sarcoma,Soft Tissue; Sarcoma; Osteosarcoma; CNS Cancer; Brain Stem Neoplasms; Breast Cancer; Cervical Cancer; Colorectal Cancer; Rectal Cancer; Colon Cancer; Esophageal Cancer; Esophagus Cancer; Cancer of Colon; Pancreatic Cancer; Cancer of Pancreas; Testis Cancer; Testicular Cancer; Ureter Cancer; Renal Cell Carcinoma; Kidney Cancer; Gestational Trophoblastic Tumor; Head and Neck Neoplasms; Parotid Tumor; Larynx Cancer; Tongue Cancer; Pharynx Cancer; Salivary Gland Cancer; Acute Myeloid Leukemia; Chronic Myeloid Leukemia; Acute Lymphoblastic Leukemia; Multiple Myeloma; Non Hodgkin Lymphoma; Carcinoid Tumor; Lung Cancer; Neuroendocrine Tumors; Mesothelioma; Thyroid Cancer; Parathyroid Neoplasms; Adrenal Cancer; Small Bowel Cancer; Stomach Cancer; ...
TY - JOUR. T1 - The impact of portal vein resection on outcomes for hilar cholangiocarcinoma. T2 - A multi-institutional analysis of 305 cases. AU - De Jong, Mechteld C.. AU - Marques, Hugo. AU - Clary, Bryan M.. AU - Bauer, Todd W.. AU - Marsh, J. Wallis. AU - Ribero, Dario. AU - Majno, Pietro. AU - Hatzaras, Ioannis. AU - Walters, Dustin M.. AU - Barbas, Andrew S.. AU - Mega, Raquel. AU - Schulick, Richard D.. AU - Choti, Michael A.. AU - Geller, David A.. AU - Barroso, Eduardo. AU - Mentha, Gilles. AU - Capussotti, Lorenzo. AU - Pawlik, Timothy M.. PY - 2012/10/1. Y1 - 2012/10/1. N2 - BACKGROUND. Surgical strategy for hilar cholangiocarcinoma often includes hepatectomy, but the role of portal vein resection (PVR) remains controversial. In this study, the authors sought to identify factors associated with outcome after surgical management of hilar cholangiocarcinoma and examined the impact of PVR on survival. METHODS: Three hundred five patients who underwent curative-intent surgery for hilar ...
Cholangiocarcinomas are a heterogeneous group of malignancies arising from a number of cells of origin along the biliary tree. Although most cases in Western countries are sporadic, large population-based studies have identified a number of risk factors. This review summarises the evidence behind reported risk factors and current understanding of the molecular pathogenesis of cholangiocarcinoma, with a focus on inflammation and cholestasis as the driving forces in cholangiocarcinoma development. Cholestatic liver diseases (e.g. primary sclerosing cholangitis and fibropolycystic liver diseases), liver cirrhosis, and biliary stone disease all increase the risk of cholangiocarcinoma. Certain bacterial, viral or parasitic infections such as hepatitis B and C and liver flukes also increase cholangiocarcinoma risk. Other risk factors include inflammatory disorders (such as inflammatory bowel disease and chronic pancreatitis), toxins (e.g. alcohol and tobacco), metabolic conditions (diabetes, obesity and non
Forest plot of extrahepatic cholangiocarcinoma risk associated with HCV infection. The pooled risk estimate was 1.75 (95% CI, 1.00 to 3.051).
Background: The aim of the present study was to analyze whether Homer1 is a potential prognostic markerfor intrahepatic cholangiocarcinoma (ICC). Materials and Methods: The expression of Homer1 in ICC tissuewas detected with immunohistochemistry and levels of protein in ICC and paratumor tissues were evaluated byWestern blotting. Survival analysis by the Kaplan-Meier method was performed to assess prognostic significance.Results: Homer1 expression was high in 67.4% (58/86) of ICC samples, and there was significant differencebetween ICC and adjacent noncancerous tissues (p|0.001); high expression was associated with poor histologicdifferentiation (p=0.019), TNM stage (p=0.014), lymph node metastasis (p=0.040), and lymphatic invasion(p=0.025). On Kaplan-Meier analysis, a comparison of survival curves of low versus high expressors of Homer1revealed a highly significant difference in OS (p=0.001) and DFS (p=0.006), indicating that high expressionof Homer1 was linked with a worse prognosis. Multivariate
Surgical resection remains the mainstay of curative treatment for intrahepatic cholangiocarcinoma (ICC). Prognosis after surgery is unsatisfactory despite improvements in treatment and post-operative clinical management. Despite developments in the molecular profiling of ICC, the preoperative prediction of prognosis remains a challenge. This study aimed to identify clinical prognostic indicators by investigating the molecular profiles of ICC and evaluating the preoperative imaging data of 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET). A retrospective analysis was performed on 50 consecutive patients with ICC who underwent curative hepatectomy after 18F-FDG-PET examination. To evaluate the molecular profiles of ICC, KRAS mutation status was assessed in resected specimens. For the assessment of glucose uptake, we observed the expression of glucose transporter-1 (GLUT-1) by immunohistochemistry. The data of 18F-FDG-PET were re-evaluated as follows: maximum standardized uptake value,
Few studies have evaluated the risk of cancers other than hepatocellular carcinoma associated with hepatitis B virus (HBV) infection. This study aimed to estimate incidence rates of intrahepatic cholangiocarcinoma (ICC) and non-Hodgkin lymphoma (NHL) and its major subtypes in a nationwide cohort of parous women and to assess their associations with chronic HBV infection. We conducted a cohort study including 1,782,401 pregnant Taiwanese women whose HBV serostatus was obtained from the National Hepatitis B Vaccination Registry. Newly diagnosed ICCs and NHLs were ascertained through data linkage with the National Cancer Registry. Risks of ICC and NHL were assessed using Cox proportional hazards regression models. After a mean of 6.91 years of follow-up, there were 18 cases of ICC and 192 cases of NHL, including 99 cases of diffuse large B-cell lymphoma (DLBCL). Incidence rates of ICC were 0.09 and 0.43 per 100,000 person-years, respectively, among women who were hepatitis B surface antigen ...
Intrahepatic cholangiocarcinoma (ICC) is an aggressive, highly lethal tumors and lacks of effective chemo and targeted therapies. Cell lines and animal models, even partially reflecting tumor characteristics, have limits to study ICC biology and drug response. In this work, we created and characterized a novel ICC patient-derived xenograft (PDX) model of Italian origin. Seventeen primary ICC tumors derived from Italian patients were implanted into NOD (Non-Obese Diabetic)/Shi-SCID (severe combined immunodeficient) mice. To verify if the original tumor characteristics were maintained in PDX, immunohistochemical (cytokeratin 7, 17, 19, and epithelial membrane antigen) molecular (gene and microRNA expression profiling) and genetic analyses (comparative genomic hybridization array, and mutational analysis of the kinase domain of EGFR coding sequence, from exons 18 to 21, exons 2 to 4 of K-RAS, exons 2 to 4 of N-RAS, exons 9 and 20 of PI3KCA, and exon 15 of B-RAF) were performed after tumor stabilization.
The aim of this study was to compare the enhancement pattern of intrahepatic cholangiocarcinoma (ICC) on contrast-enhanced ultrasound (CEUS) with that on contrast-enhanced computed tomography (CECT). 40 pathologically proven ICC lesions in 40 patients were evaluated retrospectively with both CEUS and CECT. The enhancement level and pattern in the dynamic phases on both CEUS and CECT were analysed. The diagnostic results of CEUS and CECT before pathological examination were also recorded. During arterial phases, the number of lesions that appeared as (i) peripheral irregular rim-like hyperenhancement, (ii) diffuse heterogeneous hyperenhancement, (iii) diffuse homogeneous hyperenhancement and (iv) diffuse heterogeneous hypoenhancement were 19 (47.5%), 9 (22.5%), 5 (12.5%) and 7 (17.5%), respectively, on CEUS, and 22 (55.0%), 3 (7.5%), 2 (5.0%) and 13 (32.5%), respectively, on CECT (p = 0.125). In the portal phase, the number of lesions showing hyperenhancement and hypoenhancement were 1 (2.5%) and ...
Mouse model of intrahepatic cholangiocarcinoma validates FIG-ROS as a potent fusion oncogene and therapeutic target Academic Article ...
The purpose of this project is to evaluate the role of gadoxetate (Eovist) enhanced dual-energy CT in better evaluating perihilar cholangiocarcinoma, by exploiting the combination of the physiologic behavior of gadoxetate in liver tissue combined with the advantageous mass attenuation coefficient of Gadolinium achievable through dual energy technique. This combination of unique CT imaging sensitivity, high resolution and differential enhancement potentially allows improved visualization and detection of tumor relative to enhancing surrounding hepatic parenchyma and ductal anatomy in the hepatobiliary phase, due to the biliary excretion of the agent.. Cholangiocarcinoma is a hepatic adenocarcinoma that arises from the bile duct epithelium and is the second most prevalent liver cancer after hepatocellular carcinoma. The hilar intrahepatic variety of cholangiocarcinoma can present as an infiltrative, exophytic, or polypoid lesion. Most extra-hepatic cholangiocarcinomas are infiltrative, causing a ...
OBJECTIVES: Hepatocellular carcinoma and cholangiocarcinoma form the majority of primary hepatic tumours and are the third most common cause of cancer-related deaths. These liver tumours rapidly outgrow their vascular supply and become hypoxic, resulting in the production of hypoxia inducible factors and triggering the angiogenic switch. Therefore, inhibiting angiogenesis has proven to be a valuable therapeutic strategy in hepatocellular carcinoma, yet less is known about its use in cholangiocarcinoma. In this study, we assess whether inhibiting the placental growth factor (PlGF) could offer a therapeutic option in mice with hepatocellular carcinoma and cholangiocarcinoma. PlGF is a homologue of the vascular endothelial growth factor, which is only involved in pathological angiogenesis, therefore, its inhibition does not induce adverse effects. METHODS: We have used a chemically induced transgenic mouse model in which both hepatocellular carcinoma and cholangiocarcinoma develop after 25 weeks ...
TY - JOUR. T1 - The Impact of Intraoperative Re-Resection of a Positive Bile Duct Margin on Clinical Outcomes for Hilar Cholangiocarcinoma. AU - Zhang, Xu Feng. AU - Squires, Malcolm H.. AU - Bagante, Fabio. AU - Ethun, Cecilia G.. AU - Salem, Ahmed. AU - Weber, Sharon M.. AU - Tran, Thuy. AU - Poultsides, George. AU - Son, Andre Y.. AU - Hatzaras, Ioannis. AU - Jin, Linda. AU - Fields, Ryan C.. AU - Weiss, Matthew J. AU - Scoggins, Charles. AU - Martin, Robert C.G.. AU - Isom, Chelsea A.. AU - Idrees, Kamron. AU - Mogal, Harveshp D.. AU - Shen, Perry. AU - Maithel, Shishir K.. AU - Schmidt, Carl R.. AU - Pawlik, Timothy M.. PY - 2018/2/22. Y1 - 2018/2/22. N2 - Background: The impact of re-resection of a positive intraoperative bile duct margin on clinical outcomes for resectable hilar cholangiocarcinoma (HCCA) remains controversial. We sought to define the impact of re-resection of an initially positive frozen-section bile duct margin on outcomes of patients undergoing surgery for HCCA. ...
Background and Aims: It is a challenge to collect samples from bile duct strictures to diagnose patients with cholangiocarcinoma. We investigated the utility of the Spyglass Spyscope, a single-operator endoscope that is used to perform cholangiopancreatoscopy, to identify extrahepatic cholangiocarcinoma in patients who were not diagnosed with this disorder by endoscopic retrograde cholangiopancreatography (ERCP) cytology or endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) analyses. Methods: We conducted a retrospective analysis of data from 30 patients (median age, 67 years; 67percent male) with indeterminate extrahepatic biliary strictures who were ultimately diagnosed with cholangiocarcinoma but had inconclusive results from initial biliary ductal brush cytology and EUS-FNA analyses. Patients then underwent cholangioscopy by using the Spyglass Spyscope and intraductal biopsy analysis. None of the patients had a definitive mass in abdominal imaging or EUS analyses. Results: The ...
Hepatitis B virus infection, diabetes mellitus, and their synergism for cholangiocarcinoma development: A case-control study in Korea
TRAIL in Combination with Subtoxic 5-FU Effectively Inhibit Cell Proliferation and Induce Apoptosis in Cholangiocarcinoma Cells Novel cancer therapy;TRAIL/Apo2L;non-conventional anti-cancer therapy;apoptosis; In the past decade, the incidence and mortality rates of cholangiocarcinoma (CCA) have been increasing worldwide. The relatively low responsiveness of CCA to conventional chemotherapy leads to poor overall survival. Recently, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL or Apo2L) has emerged as the most promising anti-cancer therapeutic agent since it is able to selectively induce apoptosis of tumor cells but not normal cells. In this study, we aimed to investigate the therapeutic effect of TRAIL in CCA cell lines (M213, M214 and KKU100) compared with the immortal biliary cell line, MMNK1, either alone or in combination with a subtoxic dose of 5-fluorouracil (5-FU). We found that recombinant human TRAIL (rhTRAIL) was a potential agent which significantly inhibited cell
Exosomes are part of extracellular vesicles(EVs), and can be secreted into the environment by many types of cells. It has been demonstrated that the content and function of exosomes depends on the originating cell and the conditions under which they are produced.Exosomes contain proteins,RNAs and lipid,which may transfer biological information and activities from donor cells to receptor cells. Non-coding RNAs are involved in many biological activities including tumor growth and metastasis.. In this prospective translational study, preclinical and clinical phases have been designed. On the first step, the main goal is to characterize the ncRNAs of cholangiocarcinoma derived exosomes. This exosome biomarker may provide a useful diagnostic tool. As a second step, the study will evaluate the prognostic and predictive value of cholangiocarcinoma exosomes levels in plasma in a prospectively recruited cohort of cholangiocarcinoma patients before and after surgical resection. ...
TY - JOUR. T1 - Tumor necrosis factor-α modulates epithelial mesenchymal transition mediators ZEB2 and S100A4 to promote cholangiocarcinoma progression. AU - Techasen, Anchalee. AU - Namwat, Nisana. AU - Loilome, Watcharin. AU - Duangkumpha, Kassaporn. AU - Puapairoj, Anucha. AU - Saya, Hideyuki. AU - Yongvanit, Puangrat. PY - 2014/9. Y1 - 2014/9. N2 - Background The epithelial-mesenchymal transition (EMT) process strongly contributes to cancer metastasis. This study was to investigate the alteration of EMT-related proteins (ZEB1, ZEB2 and S100A4) in cholangiocarcinoma (CCA) tissues. The effect of tumor necrosis factor-α (TNF-α) on the expression of those molecules in CCA cells was investigated. Methods The quantitative reverse transcription-polymerase chain reaction (qRT-PCR) assay was used to quantify ZEB1, ZEB2 and S100A4 mRNA levels in 50 CCA tissues and related its expression to clinicopathological data. ZEB2 protein immunostaining was investigated in 165 CCA tissues. The effect of ...
ASLAN Pharmaceuticals (ASLAN, 6497.TT), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe, today announced that it is an Oak sponsor of the Cholangiocarcinoma Foundation Annual Conference 2018 in Salt Lake City, Utah.. The conference is organised by the Cholangiocarcinoma Foundation and will be held from 31 January to 2 February 2018. Bringing together researchers, healthcare professionals, policymakers, patients and their caregivers, the conference encourages the engagement of the medical and research communities on cholangiocarcinoma by providing a forum for knowledge and innovation exchange.. For more information, please refer to the English or Chinese press release.. ...
Metastatic biliary tract cancer (BTC) has poor prognosis. Recently, patients with metastatic BTC who respond well to systemic chemotherapy can be treated by radical resection or
Postoperative Mortality after Liver Resection for Perihilar Cholangiocarcinoma: Development of a Risk Score and Importance of Biliary Drainage of the Future Liver Remnant.
BACKGROUND Surgery is the only curative therapy for patients with hilar cholangiocarcinoma (HCCA). Combined portal vein resection (PVR) could achieve negative resection margins in HCCA patients with portal vein invasion. This systematic review aimed to analysis the efficiency of combined PVR for HCCA. METHODS MEDLINE, EMBASE, the Cochrane Library, the Chinese National Knowledge Infrastructure database, and clinical trial registries were searched through April 2015. Risk ratios (RRs), and 95% confidence intervals (CIs) were calculated. RESULTS The analysis included 21 retrospective studies, altogether involving 2403 patients (patients with PVR, n=637; patients without PVR, n=1766). Patients with PVR were likely to have more advanced HCCA (lymphatic invasion: RR=1.14, 95% CI 1.02 to 1.28; perineural invasion: RR=1.31, 95% CI 1.05 to 1.63) and suffered less curative resections (RR=0.89, 95% CI 0.75 to 0.99). Postoperative morbidity was similar between patients with or without PVR (RR=1.06, 95% CI 0.94
In the west, the exact cause of cholangiocarcinoma is unclear. It is likely that this cancer arises due to a combination of factors, including other illnesses that cause chronic damage to the liver and/or bile ducts, certain toxins and possibly a small genetic predisposition, although it is not believed to be a directly inherited disease. Although most cases of cholangiocarcinoma are in people over 60 years of age, it appears to be increasing across all age groups including younger people. The cause of this ongoing rise is currently unknown.. In Southeast Asia, especially Thailand, which has the worlds highest incidence of cholangiocarcinoma, associated risk factors include eating raw fish infected with liver fluke and chronic typhoid, neither of which occurs in the western world.. ...
Hilar cholangiocarcinoma (HCCA) frequently invades into the adjacent portal vein, and portal vein resection (PVR) is the only way to manage this condition and achieve negative resection margins. However, the safety and effectiveness of PVR is controversial. Studies analyzing the effect of PVR on the surgical and pathological outcomes in the management of HCCA with gross portal vein involvement were considered eligible for this meta-analysis. The outcome variables analyzed included postoperative morbidity, mortality, survival rate, proportion of R0 resection, lymph node metastasis, microscopic vascular invasion, and perineural invasion. From 11 studies, 371 patients who received PVR and 1,029 who did not were identified and analyzed. Data from patients who received combined PVR correlated with higher postoperative death rates (OR = 2.31; 95 % CI, 1.21-4.43; P = 0.01) and more advanced tumor stage. No significant difference was detected in terms of morbidity, proportion of R0 resection, or 5-year ...
Although the incidence of hepatolithiasis is decreasing as the pattern of gallstone disease changes in Asia, the prevalence of hepatolithiasis is persistently high, especially in Far Eastern countries. Hepatolithiasis is an established risk factor for cholangiocarcinoma (CCA), and chronic proliferat …
Find the best cholangiocarcinoma doctors in Kolkata. Get guidance from medical experts to select cholangiocarcinoma specialist in Kolkata from trusted hospitals - credihealth.com
Cholangiocarcinoma is a malignant tumor that originates from the bile duct epithelium (Roberts et al., 1997). Based on its anatomical location in the biliary tree, cholangiocarcinoma is conventionally classified by the World Health Organization as an intrahepatic (ICC) or extrahepatic cholangiocarcinoma (ECC) (Bosman et al., 2010; Patel, 2011). ICC and ECC are biologically distinct, and therefore manifest substantial differences in terms of incidence, mortality, and risk factors (Cardinale et al., 2010). Cholangiocarcinoma has a poor prognosis because it is notoriously difficult to diagnose due to its late clinical presentation, and is refractory to conventional chemotherapy and radiation therapy (Blechacz and Gores, 2008; Blechacz et al., 2011; Khan et al., 2012). Gemcitabine and cisplatin has become the standard regimen for patients with advanced or metastatic cholangiocarcinoma (Ramirez-Merino et al., 2013; Valle et al., 2010). However, response to the combination chemotherapy in ...
What is Bile Duct Cancer (Cholangiocarcinoma)? Get the facts about Bile Duct Cancer (Cholangiocarcinoma) symptoms, testing, treatment and care options from trusted sources.
[504 Pages Report] Check for Discount on Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2016 report by Global Markets Direct. Global Markets Directs, Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review,...
Cholangiocarcinoma (CCA) is the second most common liver cancer and it is associated with a poor prognosis. CCA can be divided into intrahepatic, hilar and distal. Despite the subtype, the median survival is 12-24 months without treatment. Liver transplantation (LT) is worldwide recognized as a curative option for hepatocellular carcinoma. On the other hand, the initial results for LT for CCA were very poor mainly due to a lack of adequate patient selection. In the last two decades, improvement has been made in the management of unresectable hilar CCA, and the results of LT after neoadjuvant chemoradiation have been shown to be promising ...
Expression of MUC1 was detected immunohistochemically in 38 (76%) of 50 cases of m-ICC (ductal type, 18; cytoplasmic type, 20; and negative type, 12). Seventy-five percent of patients with lymph node metastasis had the cytoplasmic type MUC1 expression. Lymph node dissection was performed in only 20 patients, but significant correlation was demonstrated between MUC1 expression and lymph node metastasis (P = 0.0227). The location of MUC1 expression correlated with surgical outcome in m-ICC. Patients with the cytoplasmic type expression showed significantly lower survival rates. Univariate analysis revealed that MUC1 expression was a statistically significant risk factor affecting outcome in m-ICC (P = 0.0028). Furthermore, expression of MUC1 was found to be a statistically significant independent risk factor in multivariate analysis (P = 0.0063). ...
Background: c-MET is a proto-oncogene that encodes the tyrosine kinase receptor for hepatocyte growth factor (HGF). Activation of HGF-c-MET signaling involves cell invasiveness and evokes metastasis through direct involvement of tumor angiogenesis. However, the value of c-MET overexpression is still unknown in metastatic BTC.. Methods: We analyzed the incidence and clinicopathologic characteristics of c-MET overexpression in advanced BTC. Moreover, we investigated the value of c-MET overexpression in predicting response to gemicitabine plus cisplatin (GC), a first line standard regimen, and as a prognostic marker in metastatic BTC.. Results: The BTC subtype distribution (N=44) was as follows: intrahepatic cholangiocarcinoma (IHCC, n=7), extrahepatic cholangiocarcinoma (EHCC, n=25) and gallbladder cancer (GBC, n=12). Liver (52.3%) was the predominant metastatic site, followed by lymph nodes (36.4%) and bone (15.9%). Among the 44 patients analyzed for c-MET expression, 15 (34.1%) exhibited c-MET ...
My mother died of Cholangiocarcinoma. This is a very uncommon cancer of the bile duct. I have since that day, started this site. Not until today did I look up Cholangiocarcinoma specifically. What I just found astounds me... Was Mom taking a trial drug? A drug that wasnt even approved by the FDA? She…
Safety Profile. The most common treatment-related adverse events among all patients who received ivosidenib (including after crossover) included nausea (32.1%), diarrhea (28.8%), fatigue (23.7%), cough (19.2%), abdominal pain (18.6%), ascites (18.6%), decreased appetite (17.3%), anemia (16.0%), and vomiting (16.0%). Grade 3 adverse events were reported in 46% of patients treated with ivosidenib compared to 36% of patients treated with placebo. More of the placebo arm (8.5% vs. 5.8%) discontinued treatment due to toxicity, and ivosidenib was associated with better physical and emotional functioning on quality-of-life measures.. These pivotal data demonstrate the clinical relevance and benefit of ivosidenib in patients with IDH1-mutated cholangiocarcinoma and establish the role for genomic testing in this rare cancer with a high unmet need, Dr. Abou-Alfa said. All patients with cholangiocarcinoma should be tested for the IDH1 mutation, he maintained.. FIGHT-202. FIGHT-202 was a global, ...
BACKGROUND Intrahepatic cholangiocarcinoma is a rare condition which typically occurs in males between 50 and 70 years of age, and presents with symptoms related to biliary obstruction including jaundice, pruritus, and dark urine. Other common symptoms at presentation include abdominal pain, weight loss, and fever. CASE REPORT We present a case of a 67-year-old female initially presenting with chest pain at rest, found to have a lung nodule on diagnostic imaging at the time of admission. On further imaging, a 9 cm liver lesion was incidentally discovered, initially suspicious for hepatocellular carcinoma on imaging, with initial biopsy staining CK7 positive, and CK20 negative ...
A110 Cholangiocarcinoma (CCA), a malignant tumor of the bile duct epithelium, is one of the major of cancers in Northeast Thailand. This disease is difficult to diagnose and has a high mortality rate, thus posing an important public health problem in this region. Generally, cancer arises from dysregulation of tumor suppressor genes and oncogenes. c-Met, hepatocyte growth factor (HGF) receptor, and its ligand, HGF, regulate diverse biological responses including proliferation, migration and invasion, key features of metastatic cancer. Overexpression of c-Met has frequently been found in cholangiocarcinoma especially of well-differentiated type suggesting the role of c-Met in cholangiocarcinogenesis. In this study the role of HGF in invasiveness of cholangiocarcinoma was investigated using the human CCA cell line, KKU-213, in which c- Met expression is high when compare to immortalized cholangiocyte, H-69. Activation of c-Met by HGF induced KKU-213 cell proliferation, invasion and motility. ...
Histamine regulates functions via four receptors (HRH1, HRH2, HRH3, and HRH4). The d-myo-inositol 1,4,5-trisphosphate (IP3)/Ca2+/protein kinase C (PKC)/mitogen-activated protein kinase pathway regulates cholangiocarcinoma growth. We evaluated the role of HRH3 in the regulation of cholangiocarcinoma growth. Expression of HRH3 in intrahepatic and extrahepatic cell lines, normal cholangiocytes, and human tissue arrays was measured. In Mz-ChA-1 cells stimulated with (R)-(α)-(−)-methylhistamine dihydrobromide (RAMH), we measured (a) cell growth, (b) IP3 and cyclic AMP levels, and (c) phosphorylation of PKC and mitogen-activated protein kinase isoforms. Localization of PKCα was visualized by immunofluorescence in cell smears and immunoblotting for PKCα in cytosol and membrane fractions. Following knockdown of PKCα, Mz-ChA-1 cells were stimulated with RAMH before evaluating cell growth and extracellular signal-regulated kinase (ERK)-1/2 phosphorylation. In vivo experiments were done in BALB/c ...
Background: iCCA is the 2nd most common liver malignancy and with a poor patient prognosis. The ABC-02 study established gemcitabine+cisplatin (gem-cis) as the standard of care (SOC) in 1st line (1L) systemic chemotherapy (CT). The objective was to examine the treatment (tx) patterns and time trends in the tx received by patients (pts) with iCCA in the United States before and after ABC-02 study was published. Methods: Retrospective data from the Optum Research Database, which included commercial and Medicare Advantage health plan members between January 1, 2006 and June 30, 2018, were used. Eligible pts were aged ≥ 18 years; had ≥ 2 nondiagnostic claims of primary iCCA diagnosis (International Classification of Disease [ICD]-9: 155.1 or ICD-10: C22.1) in the identification period (July 01, 2006-March 31, 2018); and had 6 months continuous enrollment prior to and ≥ 3 months follow-up (or less due to death) from the date of first diagnosis. Tx patterns in the periods before and after ABC-02 ...
Background: Neutrophil-to-lymphocyte ratio and platelets-to-lymphocyte ratio may be host factors associated with prognosis. We sought to determine whether neutrophil-to-lymphocyte and platelets-to-lymphocyte ratio were associated with overall survival among patients undergoing surgery for intrahepatic cholangiocarcinoma. Methods: Patients who underwent resection for intrahepatic cholangiocarcinoma between 1990 and 2015 were identified from 12 major centers. Clinicopathologic factors and overall survival were compared among patients stratified by neutrophil-to-lymphocyte ratio and platelets-to-lymphocyte ratio. Risk factors identified on multivariable analysis were included in a prognostic model and the discrimination was assessed using Harrells concordance index (C index). Results: A total of 991 patients were identified. Median neutrophil-to-lymphocyte ratio and platelets-to-lymphocyte ratio were 2.7 (interquartile range [IQR]: 2.0-4.0) and 109.6 (IQR: 72.4-158.8), respectively. Preoperative ...
Sigma-Aldrich offers abstracts and full-text articles by [Maiko Terada, Kenichi Horisawa, Shizuka Miura, Yasuo Takashima, Yasuyuki Ohkawa, Sayaka Sekiya, Kanae Matsuda-Ito, Atsushi Suzuki].
This podcast is part of the 2017 NSH Symposium/Convention Poster Podcast Series. The lead author of this poster is Ruth Fidler. For more information on the author and to view the abstract, visit The Block. view more ...
High-grade dysplasia/carcinoma in situ (HGD/CIS) of the biliary duct margin was found to not affect the prognosis of patients with extrahepatic cholangiocarcinoma by recent studies, but it has not yet reached a conclusion. Eligible studies were searched by PubMed, PMC, MedLine, Embase, the Cochrane Library, and Web of Science, from Jan. 1, 2000 to Jun. 30, 2019, investigating the influences of surgical margin status of biliary duct on the prognosis of patients with resectable extrahepatic cholangiocarcinoma. Overall survival (OS) and local recurrence were evaluated by odds ratio (OR) with 95% confidence interval (CI). A total of 11 studies were enrolled in this meta-analysis, including 1734 patients in the R0 group, 194 patients in the HGD/CIS group, and 229 patients in the invasive carcinoma (INV) group. The pooled OR for the 1-, 2-, and 3-year OS rate between HGD/CIS group and R0 group was 0.98 (95% CI 0.65~1.50), 1.01 (95% CI 0.73~1.41), and 0.98 (95% CI 0.72~1.34), respectively. The pooled OR for
Conditions: Extrahepatic Bile Duct Adenocarcinoma, Biliary Type; Gallbladder Adenocarcinoma, Biliary Type; Metastatic Pancreatic Adenocarcinoma; Recurrent Cholangiocarcinoma; Recurrent Gallbladder Carcinoma; Recurrent Hepatocellular Carcinoma; Recurrent Intrahepatic Cholangiocarcinoma; Recurrent Pancreatic Carcinoma; Stage III Gallbladder Cancer AJCC V7; Stage III Hepatocellular Carcinoma AJCC v7; Stage III Intrahepatic Cholangiocarcinoma AJCC v7; Stage III Pancreatic Cancer AJCC v6 and v7; Stage IIIA Gallbladder Cancer AJCC v7; Stage IIIA Hepatocellular Carcinoma AJCC v7; Stage IIIB Gallbladder Cancer AJCC v7; Stage IIIB Hepatocellular Carcinoma AJCC v7; Stage IIIC Hepatocellular Carcinoma AJCC v7; Stage IV Gallbladder Cancer AJCC v7; Stage IV Hepatocellular Carcinoma AJCC v7; Stage IV Pancreatic Cancer AJCC v6 and v7; Stage IVA Gallbladder Cancer AJCC v7; Stage IVA Hepatocellular Carcinoma AJCC v7; Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7; Stage IVB Gallbladder Cancer AJCC v7; Stage ...
Conditions: Cholangiocarcinoma; Liver and Intrahepatic Bile Duct Carcinoma; Stage III Gallbladder Cancer AJCC v7; Stage III Intrahepatic Cholangiocarcinoma AJCC v7; Stage IIIA Gallbladder Cancer AJCC v7; Stage IIIB Gallbladder Cancer AJCC v7; Stage IV Gallbladder Cancer AJCC v7; Stage IVA Gallbladder Cancer AJCC v7; Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7; Stage IVB Gallbladder Cancer AJCC v7; Stage IVB Intrahepatic Cholangiocarcinoma AJCC v7; Unresectable Gallbladder ...
Cholangiocarcinomas (CC) frequently demonstrate lymphatic spread. We investigated lymph node (LN) counts after resection of extrahepatic CC and survival based on the SEER 1973-2004 database. Out of 20
Cholangiocarcinoma (bile duct cancer) usually develops in the bile duct system that arises from the liver and bile ducts and ends at the small intestine. Cancer that develops in the section of bile ducts within and outside the liver is called as intrahepatic and hilar cholangiocarcinoma, respectively. Distal cholangiocarcinoma is developed in the bile section that is associated with small intestine. Prognostic factors of cholangiocarcinoma are highly disputable.
Background: Cholangiocarcinoma (CCA) is a serious malignant tumor. Long non-coding RNA NNT-AS1 (NNT-AS1) takes crucial roles in several tumors. So, we planned to research the roles and underlying mechanism of NNT-AS1 in CCA.Results: NNT-AS1 overexpression was appeared in CCA tissues and cell lines. Proliferation was promoted by NNT-AS1 overexpression in CCLP1 and TFK1 cells. Besides, NNT-AS1 overexpression reduced E-cadherin level and raised levels of N-cadherin, vimentin, Snail and Slug. However, the opposite trend was occurred by NNT-AS1 knockdown. Further, NNT-AS1 overexpression promoted phosphatidylinositol 3 kinase (PI3K)/AKT and extracellular signal-regulated kinase (ERK)1/2 pathways. MiR-203 was sponged by NNT-AS1 and miR-203 mimic reversed the above promoting effects of NNT-AS1. Additionally, insulin-like growth factor type 1 receptor (IGF1R) and zinc finger E-box binding homeobox 1 (ZEB1) were two potential targets of miR-203.Conclusion: NNT-AS1 promoted proliferation, EMT and PI3K/AKT and ERK1
Cholangiocarcinoma (CCA) cells paradoxically express the death ligand tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and thus rely on potent survival signals to circumvent cell death by TRAIL. Hedgehog (Hh) signaling is an important survival pathway in CCA. Herein, we further examine the mechanisms whereby Hh signaling mediates apoptosis resistance in CCA, revealing a pivotal role for the cell division regulating serine/threonine kinase polo-like kinase 2 (PLK2). We employed 50 human CCA samples (25 intrahepatic and 25 extrahepatic CCA) as well as human KMCH-1, Mz-CHA-1, and HUCCT-1 CCA cells for these studies. In vivo experiments were conducted using a syngeneic rat orthotopic CCA model. In human samples, polo-like kinase (PLK)1/2/3-immunoreactive cancer cells were present in the preponderance of intra- and extrahepatic CCA specimens. Inhibition of Hh signaling by cyclopamine reduced PLK2, but not PLK1 or PLK3, messenger RNA and protein expression in vehicle-treated and sonic ...
Researchers are exploring how broadly liquid biopsies might be used. In the Journal of Clinical Oncology: Precision Oncology, a Mayo Clinic research team reported the array of cancer-related genetic mutations present in liquid biopsies of bile duct cancer, a form of liver cancer also known as cholangiocarcinoma. We charted the landscape of genetic alterations present in circulating tumor DNA among patients with cholangiocarcinoma, explains Dr. Mody, the articles lead author. The team evaluated liquid biopsies in one of the largest patient cohorts to date: 124 patients with cholangiocarcinoma who were treated across Mayos three campuses. Our findings provide a foundation for further development of liquid biopsies as a way to advance precision medicine for patients with cholangiocarcinoma, he says.. Cholangiocarcinoma is uncommon in the U.S., where about 5,000 new cases are diagnosed each year, though numbers have been on the rise in recent decades. The cancer is more prevalent in Southeast ...
Cancer of the bile duct (also called cholangiocarcinoma) is extremely rare. The true incidence of bile duct cancer is unknown, however, because establishing an accurate diagnosis is difficult. Traditionally, bile duct tumors located within the liver have been classified with hepatocellular carcinoma as primary liver...
Cholangiocarcinoma (CCA) - bile duct cancer - is associated with late presentation, poses challenges for diagnosis and has high mortality, features that highlig...
Aims: To compare the long-term prognosis of younger and elderly patients with combined hepatocellular-cholangiocarcinoma (CHC) who underwent curative resection between 1993 and 2014 at our center.. Methods: Two hundred and thirteen patients who underwent liver resection for CHC were enrolled in our study. The overall survival (OS) and disease-free survival (DFS) of elderly patients (age≥60, n=52) and younger patients (age,60, n=161) were compared by multivariate analysis and propensity score matching (PSM) analysis.. Results: Among the 213 CHC patients, the elderly patients had a higher rate of worse Child-Pugh grade (P=0.027), abnormal serum albumin (P,0.001) and lymphoid metastases (P=0.024). The proportion of HBV-positive CHC patients (74.6%, 159/213) was much higher than that observed in healthy cohorts. Younger patients had a higher rate of hepatitis B virus (HBV) infection compared to older patients (83.9% vs 46.2%, P,0.001). OS and DFS of the elderly and younger patients before and ...
Biliary tract cancers (BTC) comprise a group of rare and heterogeneous poor-prognosis tumours with the incidence of intrahepatic cholangiocarcinoma increasing over recent years. Combination chemotherapy with gemcitabine and cisplatin is the established first-line treatment for advanced BTC with a significant but modest survival advantage over monotherapy. There remains no accepted standard treatment in the second-line setting, although recent results from a randomised study have shown a survival benefit with 5-fluorouracil and oxaliplatin chemotherapy. Historically, clinical trials investigating targeted therapies in unselected BTC have failed to demonstrate significant clinical benefit. More recently, advancement in molecular exploration of BTC has shed light on the complex biological heterogeneity within these tumours and has also identified actionable genomic aberrations, such as fibroblast growth factor receptor 2 (FGFR2) gene fusions, isocitrate dehydrogenase (IDH) and BRAF mutations, which ...
Maffucci syndrome is characterized by the sporadic occurrence of multiple enchondromas together with multiple hemangiomas. Patients with Maffucci syndrome are at increased risk of developing different kinds of malignant tumors. We report on a 39-year-old woman who was diagnosed with Maffucci syndrome together with intrahepatic cholangiocarcinoma (IHCC). Heterozygous somatic mutations in the isocitrate dehydrogenase 1 and 2 (IDH1/IDH2) genes are associated with a number of different tumor types (e.g. IHCC) and also with Maffucci syndrome. For IHCC, mutations in IDH1/IDH2 are associated with higher survival rates. IHCC tissue as well as normal liver tissue and peripheral blood were analyzed for IDH1/IDH2-mutations in our patient. In the tumor sample, we identified a recurrent somatic IDH1-mutation affecting Arg132, while in normal liver tissue and peripheral blood, no variants were detected, as expected. This case report presents the second patient in the literature exhibiting the features of Maffucci
Background: The objective of the current study was to assess the impact of serum CA19-9 and CEA and their combination on survival among patients undergoing surgery for intrahepatic cholangiocarcinoma (ICC). Methods: Patients who underwent curative-intent resection of ICC between 1990 and 2016 were identified using a multi-institutional database. Patients were categorized into four groups based on combinations of serum CA19-9 and CEA (low vs. high). Factors associated with 1-year mortality after hepatectomy were examined. Results: Among 588 patients, 5-year OS was considerably better among patients with low CA19-9/low CEA (54.5%) compared with low CA19-9/high CEA (14.6%), high CA19-9/low CEA (10.0%), or high CA19-9/high CEA (0%) (P , 0.001). No difference in 1-year OS existed between patients who had either high CA19-9 (high CA19-9/low CEA: 70.4%) or high CEA levels (low CA19-9/high CEA: 72.5%) (P = 0.92). Although patients with the most favorable tumor marker profile (low CA19-9/low CEA) had the ...
Though much is known about the pathology of the rats liver during chemical carcinogenesis, and the associated biochemical changes have been studied extensively with some compounds, especially 4-dimethylaminoazobenzene (DAB, butter yellow), hardly any attempt has been made to follow such changes progressively or to correlate them with the histological findings. Malignant tumours of the liver are roughly divisible into cancers of the bile duct cells (cholangiocarcinomas) and those of the liver cells (hepatomas). In our experiments cholangiocarcinomas were produced by feeding thioacetamide or DAB, whereas hepatomas resulted if DAB with a vitamin B-rich diet was used. The events which decide the type of tumour which develops may be summarized thus: a cholangiocarcinoma occurs when the following changes are found in the liver, damage to parenchymal cells, proliferation of bile duct tissue, a drop in the mitochondrial fraction, and the phenomenon of ageing of mitochondria. During this time there ...
Bile duct cancer symptoms include jaundice and abdominal pain. Turn to the expert gastroenterologists at Johns Hopkins for accurate diagnosis and personalized treatment.
Looking for simple explanations to difficult medical terms that tend to puzzle you? This glossary can help you to easily understand medical terms related to the article on Bile Duct Cancer
Liver tumors: One of the major areas of my research interest liver tumors. Some of the studies have been collaborative efforts with other academic Institutions in the country, while some have been my own. We have evaluated various markers that can be applied in the diagnostic work-up of hepatocytic masses, including hepatocellular carcinoma (HCC), hepatic adenoma (HA) and focal nodular hyperplasia (FNH) over the years. Our ongoing research in this area is looking at new markers and their diagnostic utility in the work-up of hepatic masses. We are also studying the HCCs that arise in patients with cirrhosis and chronic liver disorders and compare them with those without cirrhosis and known liver disease.. One of my major areas of research interest in liver tumors is Cholangiocarcinoma (CC). It is the second most common primary malignant neoplasm of the liver. The precursor lesions of cholangiocarcinoma are not well understood. Based on observations from clinical cases, we suspect that many of ...
Evidence-based recommendations on endoscopic bipolar radiofrequency ablation for biliary obstruction caused by bile duct and pancreas cancers..
Over the past decade, it has become apparent that the human polybromo-1 protein (BAF180) has a critical role in cancer. BAF180 is known to be a driver mutation in clear cell renal cell carcinoma, where it has been found to be mutated in approximately 40% of cases. Mutations have also been found in several other cancers, including intrahepatic cholangiocarcinomas and epithelioid sarcomas. BAF180 is the chromatin targeting subunit of the PBAF (Polybromo-associated BRG1-associated factor) chromatin remodeling complex, a role facilitated by its nine domains: six bromodomains, which recognize and bind to acetylated lysines on histones; two BAH (bromo-adjacent homology) domains, found to be critical for PCNA ubiquitination following DNA damage; and one HMG (high mobility group) box, the DNA binding component. Furthermore, proper expression of BAF180 has also been linked to cardiac development and cell cycle regulation. Despite these associations, the molecular level interactions of full-length BAF180 have yet
Exome sequencing reveals frequent inactivating mutations in BAP1, ARID1A, and PBRM1 in intrahepatic cholangiocarcinomas. Jiao Y, Pawlik TM, Anders RA, Selaru FM, Streppel MM, Lucas DJ, Niknafs N, Guthrie VB, Maitra A, Argani P, Offerhaus GJA, Roa JC, Roberts LR, Gores GJ, Popescu I, Alexandrescu ST, Dima S, Fassan M, Simbolo M, Mafficini A, Capelli P, Lawlor RT, Ruzzenente A, Guglielmi A, TortoraG, de Braud F, Scarpa A, Jarnagin W, Klimstra D, Karchin R, Velculescu VE, Hruban RH, Vogelstein B, Kinzler KW, Papadopoulos N, Wood LD. Nat Genet. 2013 Dec; 45(12):1470-3 ...
HISTOLOGY: HEPATOBILIARY: LIVER: BILIARY: Cholangiocarcinoma: Micro high mag H&E growth along wall of portal vein not too sure that this case would be called cholangiocarcinoma today more like a hepatoma see also. ...
Dear All. Just updating on Mum.. We have had a bit of a rollercoaster over the last few months.. Mum was started on FOLFOX back in June…after having completed 11 Cycles of GEM/CIS. GEM/CIS was well tolerated.. FOLFOX was not so well tolerated and following two cycles was suspended by Mums oncologist. Main problem was tummy pains/some ascites. Not sure, however, whether the tummy pains were the chemo or the anti-sickness drugs.. Bone mets continue to wreak pain and we were fire fighting with radiotherapy. Then two weekends ago Mum woke up to such pain in her cervical vertebrae that we had to have her hospitalised. We thought she had fractured her neck or it was spinal cord compression. AN MRI confirmed it was just bone mets. She was discharged from hospital 3 days later with a new medication list, and a prescription for five fractions of radiotherapy to the cervical vertebrae area.. We followed the new pain medication list (which caused periodic wipe out for Mum) because it included diazepam ...
I was extracting information on Neill, husband of Cindy Russell for a foundation database, when I ran across references to the controversial Dr. Jerome Canady. Neill posted on these boards from 10/31/07 - 11/27/07 and on his own web site. According to him, Dr. Canady used his invention, the Plasma Beam Catheter to remove every vestige of cancerous tumor at the cellular level that had been wrapped around the arteries and veins of Cindys liver. Doctors from John Hopkins, Mayo Clinic, and Pittsburg UPMC had said she was inoperable and gave her no more than 6 months to live. The case was reported on television news. Cindy passed away on 16 Nov 2009, having survived 2.35 years since her surgery and 2.69 years since her diagnosis, well over her 6 month expectation.. Dr. Canady presently is associated with the Canady Surgical Group in Washington, DC. He refers to his invention now as a Plasma Surgical Scapel, with scalpel spelled scapel. I couldnt find any other information on this device by ...
Abou-Alfa GK, Andersen JB, Chapman W, Choti M, Forbes SJ, Gores GJ, Hong TS, Harding JJ, Vander Heiden MG, Javle M, Kelley RK, Kwong LN, Lowery M, Merrell A, Miyabe K, Rhim A, Saha S, Sia D, Tanasanvimon S, Venook A, Valle JW, Walesky C, Whetstine J, Willenbring H, Zhu AX, Mayer D, Stanger BZ. Advances in cholangiocarcinoma research: report from the third Cholangiocarcinoma Foundation Annual Conference. J Gastrointest Oncol. 2016 Dec; 7(6):819-827 ...
Catherine Jane Midgley Sorenson, 1949 - 2011. On December 31, 2011, Cathys courageous fight with cancer ended and she returned home to her Heavenly Father. Cathy was born March 23, 1949 in Salt Lake City, Utah to Frank Park and Nedra Midgley, the sixth of eight children. From an early age, Cathy had a special relationship with her parents and valued family. Some of her fondest childhood memories were visiting her grandparents in California and their visits to Utah. In 1967, Cathy graduated from East High School in Salt Lake City. After some schooling in Chicago, she returned to Salt Lake where she continued to work until she met Jay Parson Sorenson. She and Jay were married on May 20, 1977 and he has been her eternal companion since that time. Cathy and Jay quickly started a family and are parents to five children. Her family, including her husband, five children, their spouses, and her eight grandchildren were the center of her life as she was an amazing wife, mom, grandmother, sister, aunt, ...
Cholangiocarcinoma (CCA) is a fatal cancer of the bile duct epithelial cell lining. The misdiagnosis of CCA and other biliary diseases may occur due to the similarity of clinical manifestations and blood tests resulting in inappropriate or delayed treatment. Thus, an accurate and less-invasive method for differentiating CCA from other biliary diseases is inevitable. We quantified methylation of OPCML, HOXA9, and HOXD9 in serum cell-free DNA (cfDNA) of CCA patients and other biliary diseases using methylation-sensitive high-resolution melting (MS-HRM). Their potency as differential biomarkers between CCA and other biliary diseases was also evaluated by using receiver operating characteristic (ROC) curves. The significant difference of methylation levels of OPCML and HOXD9 was observed in serum cfDNA of CCA compared to other biliary diseases. Assessment of serum cfDNA methylation of OPCML and HOXD9 as differential biomarkers of CCA and other biliary diseases showed the area under curve (AUC) of 0.850 (0
Lung scarring can be a highly dangerous condition and is usually caused by inhaling dangerous chemicals or by infections. Lung scarring is generally defined by which area of the lung is injured, with the perihilar area, which is the major entrance for the major veins and arteries of the lungs, being the most common.
Researchers in radiology at Memorial Sloan Kettering continue to assess multiple imaging methods in the quest to improve treatment options and success rates for patients with biliary cancers such as cholangiocarcinoma.
Dr. Stegalls Comments: There are many theories as to how cancer develops, and one of them is that cancer starts as a bacteria. The idea that bacteria could cause cholangiocarcinoma is an interesting one, as it would suggest a possible target for treatment using off-label antibiotic regimens. I typically include a low dose antibiotic given intravenously in periodic fashion as part of my treatment protocols, in case there is a bacterial component ...
Cell lines and human tissue samples. Cell lines from four human pancreatic carcinomas (SU8686, AsPC1, BxPC3, and CFPAC1), two gastric cancers (AGS and MKN7), three hepatic carcinomas (Alexander, Hep3B, and HepG2), a cholangiocarcinoma (HuCCT), and embryonic kidney (HEK293T) were purchased from the American Type Culture Collection (Manassas, VA) or the Japanese Riken Cell Bank (Tsukuba, Japan). Normal hepatocytes were purchased from Dainippon Pharma (Osaka, Japan) and normal diploid colonocytes (CCD841) were purchased from American Type Culture Collection. Tissue specimens obtained during surgery or endoscopic resection were obtained from the University of Tokyo Hospital (Tokyo, Japan) and Motojima Memorial Hospital (Gumma, Japan) after approval from the medical ethics committee and the acquisition of informed consent. Some samples of colonic cancer and surrounding precancerous tissue were collected from identical specimens. Formalin-fixed, paraffin-embedded sections were examined by H&E staining ...
In cases of biliary stasis, detoxification can be problematic for the client and the therapist, so improving biliary flow should be a consideration. Biliary tract disease is on the increase with cholangiocarcinoma occurring in 65% of cases with recurring symptoms from gallstones in the over-65s. Patients who fall into the fair, fat, forty and fertile category are also at increased risk. Alteration ...
The key purpose of the main part of the study is to assess efficacy and safety of anetumab ravtansine as monotherapy or combination therapy for mesothelin expressing advanced solid tumors. The main purpose of the safety lead-in (dose-finding) part of the study is to determine the safety and tolerability of anetumab ravtansine in combination with cisplatin and in combination with gemcitabine, and to determine the MTD of anetumab ravtansine in combination with cisplatin for mesothelin expressing advanced cholangiocarcinoma and in combination with gemcitabine for mesothelin expressing advanced adenocarcinoma of the pancreas. Patients will receive anetumab ravtansine every three weeks in monotherapy for most indications. In cholangiocarinoma and adenocarinoma of the pancreas, 3-weekly anetumab ravtansine is administered in combination with cisplatin or gemcitabine respectively (both administered in a 2 week on / 1 week off schedule). Treatment will continue until disease progression or until another ...
Venturini M, et al. Chemoembolization with drug eluting beads preloaded with irinotecan (DEBIRI) vs doxorubicin (DEBDOX) as a second line treatment for liver metastases from cholangiocarcinoma: A preliminary study. British Journal of Radiology 89: 20160247, No. 1067, Nov 2016. Available from: URL: http://doi.org/10.1259/bjr.20160247 - Italy ...
Silmitasertib is currently in a Phase 2 randomized trial for cholangiocarcinoma, and has proven to be safe and well-tolerated in human.
Cholangiocarcinoma or bile duct cancer is a form of cancer that is composed of mutated epithelial cells (or cells showing ... Cholangiocarcinoma is considered to be an incurable and rapidly lethal cancer unless both the primary tumor and any metastases ... The Cholangiocarcinoma Foundation The Johns Hopkins Gall Bladder & Bile Duct Cancer Web page Bile+Ducts at the US National ... cholangiocarcinoma, cancer of the bile ducts; blockage by a stone in patients with gallstones; and from scarring after injury ...
Cholangiocarcinoma, or cancer of the bile duct, is an indication for the Whipple procedure when the cancer is present in the ... Depending on the location and extension of the cholangiocarcinoma, curative surgical resection may require hepatectomy, or ... "Advances in the surgical treatment of hilar cholangiocarcinoma". Expert Review of Gastroenterology & Hepatology. 9 (3): 369-374 ...
Cholangiocarcinoma commonly occurs in patients with repeated episodes of cholangitis. Performing an anastomosis alters the ...
... cholangiocarcinoma, uterine carcinosarcoma, uveal melanoma, thymoma, sarcoma, mesothelioma, and testicular germ cell cancer. ... "Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles". Cell Reports. 18 (11): ...
... fibrolamellar carcinoma and cholangiocarcinoma". Journal of Hepatology. 30 (3): 519-26. doi:10.1016/S0168-8278(99)80114-7. PMID ...
He died of cholangiocarcinoma in his home in Dubuque, Iowa, on Halloween 2000. Won awards at Harvard for creative writing; ...
... fibrolamellar carcinoma and cholangiocarcinoma". Gastroenterology. 114: A1219. doi:10.1016/s0016-5085(98)84945-7. ISSN 0016- ...
... death receptor-4 and promotes apoptosis resistance in cholangiocarcinoma". Hepatology. 55 (2): 465-75. doi:10.1002/hep.24698. ...
Distomiasis, caused by parasitic liver flukes, is associated with cholangiocarcinoma (cancer of the bile duct) in East Asia. ... cholangiocarcinoma). Infection is the fourth most important risk factor for cancer mortality in the developed world, causing ...
"Lupeol and stigmasterol suppress tumor angiogenesis and inhibit cholangiocarcinoma growth in mice via downregulation of tumor ...
On 10 April 2018, Li died from intrahepatic cholangiocarcinoma at Tsinghua Changgeng Hospital in Beijing, at the age of 47. "电视 ...
Alternatively, the portal vein may be injured as a result of pancreatitis, diverticulitis, cholangiocarcinoma, hepatocellular ...
June 2013). "Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share ...
Cholangiocarcinoma 2009-06-08 Coeliac disease 2008-05-18 Dengue fever 2011-08-05 ...
Multiphasic MRI is useful in diagnosing various types of liver lesions such as hepatocellular carcinoma, cholangiocarcinoma, ...
... cholangiocarcinoma). Inflammation triggered by the worm's eggs appears to be the cancer-causing mechanism. Certain parasitic ...
Cancers of the biliary tree, including cholangiocarcinoma. Colorectal cancer is a disease of old age: It typically originates ...
"Paraneoplastic porphyria cutanea tarda associated with cholangiocarcinoma: Case report". The Turkish Journal of ...
Initial presentation and management of hilar and peripheral cholangiocarcinoma: is a node-positive status or potential margin- ...
... cholangiocarcinoma, gastric cance, musculoskeletal diseases, etc. Translational Medicine programme is an international ...
... cholangiocarcinoma - cholangiosarcoma - cholelith - cholestasis - chondrocyte - chondroitin sulfate - chondrosarcoma - chordoma ...
... liver cell carcinoma hepatocellular carcinoma hepatoma cholangiocarcinoma hepatoblastoma angiosarcoma of liver Kupffer cell ...
These include: Alzheimer's disease atherosclerosis cholangiocarcinoma Crohn's disease chronic fatigue syndrome dysautonomia ...
Text is available under the Creative Commons Attribution/Share-Alike License and the GFDL; additional terms may apply. See Terms of Use for details ...
Rustagi T, Dasanu CA (2012). "Risk Factors for Gallbladder Cancer and Cholangiocarcinoma: Similarities, Differences and Updates ... "Liver fluke induces cholangiocarcinoma". PLoS Medicine. 4 (7): 1148-1155. doi:10.1371/journal.pmed.0040201. PMC 1913093 . PMID ...
Ben-Menachem T (August 2007). "Risk factors for cholangiocarcinoma". Eur J Gastroenterol Hepatol. 19 (8): 615-7. doi:10.1097/ ...
Other causes include strictures of the common bile duct, biliary atresia, cholangiocarcinoma, pancreatitis, cholestasis of ...
"Secretin inhibits cholangiocarcinoma growth via dysregulation of the cAMP-dependent signaling mechanisms of secretin receptor ...
2010). "Secretin inhibits cholangiocarcinoma growth via dysregulation of the cAMP-dependent signaling mechanisms of secretin ...
Food and Drug Administration for cholangiocarcinoma and is currently in phase II study. Silmitasertib is being developed by ...
Cholangiocarcinoma is a group of cancers that begin in the bile ducts. Explore symptoms, inheritance, genetics of this ... cholangiocarcinoma.. The three types of cholangiocarcinoma do not usually cause any symptoms in their early stages, and this ... Cholangiocarcinoma is classified by its location in relation to the liver. Intrahepatic. cholangiocarcinoma begins in the small ... Cholangiocarcinoma is not inherited. Studies suggest that blood relatives of a person with cholangiocarcinoma may have an ...
Cholangiocarcinoma: Evolving concepts and therapeutic strategies. Nat Rev Clin Oncol. 2018 Mar;15(2):95-111. ... Cholangiocarcinoma: Evolving concepts and therapeutic strategies. Nat Rev Clin Oncol. 2018 Mar;15(2):95-111. ... Physician Data Query (PDQ). Bile Duct (Cholangiocarcinoma) Cancer Treatment. 03/14/2018. Accessed at https://www.cancer.gov/ ... Physician Data Query (PDQ). Bile Duct (Cholangiocarcinoma) Cancer Treatment. 03/14/2018. Accessed at https://www.cancer.gov/ ...
AMMF is the UKs only cholangiocarcinoma charity. Our main aims are to raise the awareness of cholangiocarcinoma (bile duct ... AMMF is the UKs only cholangiocarcinoma charity. Our main aims are to raise the awareness of cholangiocarcinoma (bile duct ... AMMF Cholangiocarcinoma Awareness Month 2019. Thank you for taking the time to visit AMMFs 2019 Awareness Month JustGiving ... Each day throughout February, AMMF are encouraging all our supporters to raise awareness of cholangiocarcinoma and also raise ...
... of our study was to evaluate the imaging features and patterns of contrast enhancement in peripheral cholangiocarcinomas with ... Methods: We reviewed the CT scans of 24 patients with 25 peripheral cholangiocarcinomas proved by orthotopic liver ... and contrast enhancement on delayed images are highly suggestive of peripheral intrahepatic cholangiocarcinoma. ... of our study was to evaluate the imaging features and patterns of contrast enhancement in peripheral cholangiocarcinomas with ...
Drugs & Diseases , Oncology , Cholangiocarcinoma Q&A What are the differential diagnoses for Cholangiocarcinoma?. Updated: Dec ... Cholangiocarcinoma - evolving concepts and therapeutic strategies. Nat Rev Clin Oncol. 2018 Feb. 15 (2):95-111. [Medline]. [ ... Intra-hepatic cholangiocarcinoma--frequency and demographic patterns: thirty-year data from the M.D. Anderson Cancer Center. J ... Hilar and suprapancreatic cholangiocarcinoma: value of 3D angiography and multiphase fusion images using MDCT. AJR Am J ...
Mutational landscape of intrahepatic cholangiocarcinoma.. Zou S1, Li J2, Zhou H1, Frech C3, Jiang X1, Chu JS4, Zhao X3, Li Y1, ... Intrahepatic cholangiocarcinoma (ICC) is a fatal primary liver cancer (PLC) that affects 5-10% of all PLCs. Here we sequence ...
Image Tag: Cholangiocarcinoma. Endoscopic view of a choledochojejunal anastomosis. Endoscopic view of a choledochojejunal ... anastomosis, cholangiocarcinoma, choledochojejunal, distal, endoscopic, gastrointestinal bleed, obstructive jaundice, ... side-to-side choledochojejunostomy had been performed 2 months previously for an unresectable distal cholangiocarcinoma causing ...
Cholangiocarcinoma staging is a process used by physicians to describe bile duct cancer in standardized terms regarding the ... Most cholangiocarcinoma staging systems use a numerical scale ranging from 1 through 4, with higher numbers corresponding to ... If youd like to learn more about cholangiocarcinoma staging, the bile cancer experts at Moffitt can explain the statistics and ... The most widely used system is the American Joint Committee on Cancer (AJCC) TNM system, which bases the cholangiocarcinoma ...
For these reasons, cholangiocarcinoma is usually found only after the cancer has advanced enough to cause symptoms. In the ... Cholangiocarcinoma screening cannot be performed with any degree of reliability in individuals who are not experiencing ... If you have questions about cholangiocarcinoma screening and early detection, contact the experts at Moffitt by calling 1-888- ... Because there is currently no cholangiocarcinoma screening method recommended for routine use in the general population, early ...
cholangiocarcinoma synonyms, cholangiocarcinoma pronunciation, cholangiocarcinoma translation, English dictionary definition of ... cholangiocarcinoma. Translations. English: cholangiocarcinoma n colangiocarcinoma m. Spanish / Español: n colangiocarcinoma m. ... In adults the most common tumor was HCC (47%) followed by cholangiocarcinoma (11.7%) and metastatic disease in one patient from ... Devkota was diagnosed Bile Duct Cancer Cholangiocarcinoma at the London-based Kings College Hospital.. Dr Devkota passes away ...
Cholangiocarcinomas (bile duct cancers) arise from the epithelial cells of the bile ducts. Although they are rare in the United ... Intrahepatic cholangiocarcinomas can originate from either small intrahepatic ductules (peripheral cholangiocarcinomas) or ... See Epidemiology, pathogenesis, and classification of cholangiocarcinoma and Treatment of localized cholangiocarcinoma: ... Differentiating combined hepatocellular and cholangiocarcinoma from mass-forming intrahepatic cholangiocarcinoma using ...
... Muharrem Battal,1 Bünyamin Gürbulak,2 Ozgür Bostanci,1 ... Malignant hypercalcemia and thrombocytopenia may result from bone metastasis of cholangiocarcinoma (CC). Our case was 53-year- ...
... particularly nitrative and oxidative DNA damage and the clinical manifestations of cholangiocarcinoma. ... Lim JH (2003) Cholangiocarcinoma: Morphologic classification according to growth pattern and imaging findings. AJR Am J ... Sirica AE (2005) Cholangiocarcinoma: Molecular targeting strategies for chemoprevention and therapy. Hepatology 41: 5-15. * ... Anderson CD, Pinson CW, Berlin J, Chari RS (2004) Diagnosis and treatment of cholangiocarcinoma. Oncologist 9: 43-57. * View ...
Age-standardized mortality rates from intrahepatic (IC) and extrahepatic (EC) cholangiocarcinoma for men and women, by country. ... Cholangiocarcinoma, also known as bile duct cancer, is a type of cancer that forms in the bile ducts.[2] Symptoms of ... Darwin PE, Kennedy A. Cholangiocarcinoma at eMedicine *^ Zervos EE, Osborne D, Goldin SB, Villadolid DV, Thometz DP, Durkin A, ... Cholangiocarcinoma is rare in the Western world, with estimates of it occurring in 0.5-2 people per 100,000 per year.[1][6] ...
Bile duct carcinoma (cholangiocarcinoma) is a cancer of the bile ducts, the tubes that connect the liver and gall bladder to ...
Does intrahepatic cholangiocarcinoma have better prognosis compared to perihilar cholangiocarcinoma?. J Surg Oncol. 2010 Feb 1 ... Drugs & Diseases , Radiology , Cholangiocarcinoma Imaging Q&A Which imaging modalities are used in the workup of ... Intrahepatic cholangiocarcinoma: MRI and pathologic correlation in 14 patients. J Comput Assist Tomogr. 1997 Jan-Feb. 21(1):59- ... Olthof SC, Othman A, Clasen S, Schraml C, Nikolaou K, Bongers M. Imaging of Cholangiocarcinoma. Visc Med. 2016 Dec. 32 (6):402- ...
Cholangiocarcinoma is the second most frequent primary neoplasm of the liver and its incidence is increasing in Western ... tract and can be categorized according to their anatomical location as intrahepatic and extrahepatic cholangiocarcinomas. The ... Cholangiocarcinoma is the second most frequent primary neoplasm of the liver and its incidence is increasing in Western ... This book contains an up-to-date review of diagnostic and staging tools of cholangiocarcinoma, and of long-term outcome of ...
Workflow of the Cholangiocarcinoma Screening and Car Program (CASCAP). CCA = cholangiocarcinoma, U/S = ultrasonography, CT = ... Cohort profile: cholangiocarcinoma screening and care program (CASCAP).. Khuntikeo N1,2, Chamadol N3,4, Yongvanit P3,5, Loilome ... Cholangiocarcinoma Screening and Care Program (CASCAP), Khon Kaen University, Khon Kaen, 40002, Thailand. [email protected] 12 ... The Cholangiocarcinoma Screening and Care Program (CASCAP) is a prospective cohort study comprising two cohorts- the screening ...
A biopsy confirmed that she had intrahepatic cholangiocarcinoma, more commonly known as bile duct cancer. ... Tags: Bile, Bile Duct Cancer, Biopsy, Cancer, Carcinoma, Chemotherapy, Cholangiocarcinoma, Cirrhosis, Clinical Trial, CT, CT ... Study offers new hope for patients with intrahepatic cholangiocarcinoma. *Download PDF Copy ... Ghobrial said most patients with intrahepatic cholangiocarcinoma were found to have this type of cancer only after they ...
See a list of publications on cholangiocarcinoma by Mayo Clinic doctors on PubMed, a service of the National Library of ... Researchers at Mayo Clinic are studying new ways to diagnose and treat cholangiocarcinoma. This research is conducted as part ...
See a list of publications on cholangiocarcinoma by Mayo Clinic doctors on PubMed, a service of the National Library of ... Researchers at Mayo Clinic are studying new ways to diagnose and treat cholangiocarcinoma. This research is conducted as part ... Anal cancer, Cholangiocarcinoma, Colon cancer, Esophageal cancer, Hepatocellular carcinoma, Liver cancer, Pancreatic cancer, ... Kidney transplant, Liver transplant, Living-donor transplant, Pancreas transplant, Cholangiocarcinoma, Gallbladder cancer, ...
... (Type 4). DISCUSSION. Patients with cholangiocarcinoma most often present with painless jaundice ... Cholangiocarcinomas are divided into intrahepatic, extrahepatic (perihilar), and distal extrahepatic cholangiocarcinoma. The ... These include squamous and mucinous cholangiocarcinoma. Cholangiocarcinoma may also be broken down by growth pattern: exophytic ... Perihilar cholangiocarcinoma. By Brian J. Di Giacinto, BS, OMS IV; Ashley M. Bohn, BS, OMS IV; and Amit K. Sanghi, BS, DO ...
This topic contains 11 study abstracts on Cholangiocarcinoma indicating that the following substances may be helpful: ... Diseases : Cholangiocarcinoma. Pharmacological Actions : Anti-Inflammatory Agents, Anti-Proliferative, Chemopreventive, Matrix ... Diseases : Cholangiocarcinoma. Pharmacological Actions : Antineoplastic Agents, Apoptotic, Tumor Necrosis Factor (TNF) Alpha ... Diseases : Cholangiocarcinoma. Pharmacological Actions : Antineoplastic Agents, Antiproliferative , Apoptotic, STAT3 Inhibitor ...
Office of Orphan Products Development has granted Orphan Drug Designation for melphalan for the treatment of cholangiocarcinoma ... Intrahepatic cholangiocarcinoma (ICC), a sub-category of cholangiocarcinoma, is a tumor in the bile duct that arises within the ... Cholangiocarcinoma is recognized by the FDA as an orphan disease, usually defined as a condition that affects fewer than ... Tags: Bile, Cancer, Chemotherapy, Cholangiocarcinoma, Clinical Trial, Liver, Liver Cancer, Melanoma, New Drug Application, ...
Cholangiocarcinoma (CCA), cancer of the bile duct, is the first cause of cancer death of the people in the northeast of ... Calcitriol in Advanced Intrahepatic Cholangiocarcinoma. The safety and scientific validity of this study is the responsibility ... Cholangiocarcinoma. Adenocarcinoma. Carcinoma. Neoplasms, Glandular and Epithelial. Neoplasms by Histologic Type. Neoplasms. ... Department of Surgery, Faculty of Medicine, Liver fluke and cholangiocarcinoma research center, Khon Kaen University. ...
ncRNAs in Exosomes of Cholangiocarcinoma. The safety and scientific validity of this study is the responsibility of the study ... Cholangiocarcinoma. Adenocarcinoma. Carcinoma. Neoplasms, Glandular and Epithelial. Neoplasms by Histologic Type. Neoplasms. ... MedlinePlus Genetics related topics: Cholangiocarcinoma Genetic and Rare Diseases Information Center resources: Bile Duct ... On the first step, the main goal is to characterize the ncRNAs of cholangiocarcinoma derived exosomes. This exosome biomarker ...
Bile Duct Cancer (Cholangiocarcinoma) Treatment. General Information About Bile Duct Cancer. Key Points for this Section. *Bile ... Carcinoid & Neuroendocrine Tumors Cervical Cancer Cholangiocarcinoma Chronic Lymphocytic Leukemia (CLL) Chronic Myelogenous ... Distal extrahepatic bile duct cancer is also called extrahepatic cholangiocarcinoma.. Anatomy of the extrahepatic bile ducts. ... Intrahepatic bile duct cancers are also called intrahepatic cholangiocarcinomas.. Anatomy of the intrahepatic bile ducts. ...
Bile Duct Cancer (Cholangiocarcinoma) - About Clinical Trials up Bile Duct Cancer (Cholangiocarcinoma) - Coping With Treatment ... Bile Duct Cancer (Cholangiocarcinoma): Latest Research. Approved by the Cancer.Net Editorial Board, 01/2019 ...
... cholangiocarcinoma) from the Cleveland Clinic, including information on treatment options, stages & more. ... Cholangiocarcinoma is difficult to cure and many cases are sporadic with no identifiable etiology or cause. ... Bile duct cancer is called cholangiocarcinoma. It arises from the epithelium or biliary tree lining either within the liver or ... Liver transplantation is currently an effective method of treatment for cholangiocarcinoma of the hilum of the liver in patient ...
  • Perihilar cholangiocarcinoma (also known as a Klatskin tumor) begins in an area called the hilum, where the right and left major bile ducts join and leave the liver. (medlineplus.gov)
  • In most cases of cholangiocarcinoma, these genetic changes are acquired during a person's lifetime and are present only in the bile duct cells that give rise to the tumor. (medlineplus.gov)
  • Ramage JK, Donaghy A, Farrant JM, Iorns R, Williams R. Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. (medscape.com)
  • Preoperative Bilirubin Level Predicts Overall Survival and Tumor Recurrence After Resection for Perihilar Cholangiocarcinoma Patients. (medscape.com)
  • Cholangiocarcinoma staging is a process used by physicians to describe bile duct cancer in standardized terms regarding the size of a tumor and the extent of its spread. (moffitt.org)
  • PureTech's immuno-oncology program, LYT-200, is a fully human, potentially first-in-class, IgG4 monoclonal antibody designed to target galectin-9, which is a fundamental immunosuppressive mechanism in hard-to-treat cancers such as pancreatic, colorectal, and cholangiocarcinoma , among other tumor types. (thefreedictionary.com)
  • In adults the most common tumor was HCC (47%) followed by cholangiocarcinoma (11.7%) and metastatic disease in one patient from Pancreatic Neuroendocrine Origin (5%) shown in fig-2. (thefreedictionary.com)
  • Consistent with this observation, microscopic tumor infiltration of the caudate lobe can be found in many patients with perihilar cholangiocarcinoma (12). (thefreedictionary.com)
  • The most common physical indications of cholangiocarcinoma are abnormal liver function tests , jaundice (yellowing of the eyes and skin occurring when bile ducts are blocked by tumor), abdominal pain (30-50%), generalized itching (66%), weight loss (30-50%), fever (up to 20%), and changes in the color of stool or urine . (wikipedia.org)
  • [9] [10] To some extent, the symptoms depend upon the location of the tumor: people with cholangiocarcinoma in the extrahepatic bile ducts (outside the liver) are more likely to have jaundice, while those with tumors of the bile ducts within the liver more often have pain without jaundice. (wikipedia.org)
  • The tumor in this case was a type IV cholangiocarcinoma with multi-focal involvement extending from the confluence of the hepatic ducts to the common bile duct (Table 2). (appliedradiology.com)
  • Intrahepatic cholangiocarcinoma (ICC), a sub-category of cholangiocarcinoma, is a tumor in the bile duct that arises within the liver. (news-medical.net)
  • The current study is set up a clinical trial phase II of vitamin D (calcitriol) in combination with 5-fluorouracil, Mitomycin C and Leucovorin in an open label-non-randomized study to evaluate the tumor response in patients with advanced intrahepatic cholangiocarcinoma. (clinicaltrials.gov)
  • Perihilar bile duct cancer is also called a Klatskin tumor or perihilar cholangiocarcinoma. (oncolink.org)
  • Here, we show in a metastatic cholangiocarcinoma with ERBB2 amplification identified on liquid biopsy (circulating tumor DNA (ctDNA) testing), a dramatic response to now over 12 months of dual-anti-HER2 therapy. (nature.com)
  • Cholangiocarcinoma (CCA) is a lethal tumor arising from the epithelium of the bile ducts that most often presents at an advanced stage. (nature.com)
  • Furthermore, due to the relative rarity of this tumor when compared to hepatocellular carcinoma, only a few reports have focused on short and long-term results for intrahepatic cholangiocarcinoma. (sages.org)
  • Cholangiocarcinoma, or bile duct cancer, occurs when a malignant (cancerous) tumor grows in one of the ducts that transport bile from the liver to the small intestine. (hopkinsmedicine.org)
  • Cholangiocarcinoma, also called bile duct cancer, occurs when a cancerous tumor grows in the bile ducts. (hopkinsmedicine.org)
  • Defined as an intrahepatic tumor nodule that contains both hepatocellular carcinoma and cholangiocarcinoma . (atlasgeneticsoncology.org)
  • The most effective treatment for cholangiocarcinoma is surgery to remove the tumor. (knowcancer.com)
  • Cholangiocarcinoma (CCA), a malignant tumor of the bile duct epithelium, is one of the major of cancers in Northeast Thailand. (aacrjournals.org)
  • Down-regulation of Fas enables cells to escape Fas-induced apoptosis and is correlated with increased tumor size and short survival of the patients with cholangiocarcinoma. (aacrjournals.org)
  • Cholangiocarcinoma (CCA) is the tumor arising from the bile duct epithelium. (sigmaaldrich.com)
  • Immunohistochemical expression of HSP90 was assessed retrospectively in 399 cholangiocarcinoma cases and 17 human cholangiocarcinoma cell lines, along with the effect of a small-molecule HSP90 inhibitor (NVP-AUY922) on cholangiocarcinoma tumor growth and angiogenesis in human cholangiocarcinoma cell lines and xenografts. (aacrjournals.org)
  • That was a deliberate strict inclusion of patients into this study to introduce minimal genomic heterogeneity, because cholangiocarcinoma is a tumor type that exists both in the liver and right outside the liver (extrahepatic). (onclive.com)
  • Cholangiocarcinoma is a malignant tumor arising from cholangiocytes in the biliary tree. (radiopaedia.org)
  • It is the second most common primary hepatic tumor , with intrahepatic cholangiocarcinomas (ICCs) accounting for 10-20% of primary liver tumors. (radiopaedia.org)
  • Cholangiocarcinoma (CCA), a malignant tumor of the bile duct, is a major public health problem in many Southeast Asian countries, particularly Thailand. (ajtmh.org)
  • Have a histopathological diagnosis (fresh or banked tumor biopsy sample, preferably collected within the last 3 years) of nonresectable or metastatic cholangiocarcinoma and are not eligible for curative resection, transplantation, or ablative therapies. (mayo.edu)
  • Combined hepatocellular carcinoma-cholangiocarcinoma is a histopathologically distinct tumor for which no formal treatment guidelines exist. (ascopost.com)
  • He added that survival with this mixed tumor type appears to be better than is typically seen with either hepatocellular carcinoma or cholangiocarcinoma. (ascopost.com)
  • With the availability of multiple tumor markers, more cases of mixed hepatocellular carcinoma-cholangiocarcinoma are being detected. (ascopost.com)
  • Dr. Kapur concluded that multicenter data are needed to better understand the clinical behavior of this tumor and determine tailored treatment, "rather than treating it like hepatocellular carcinoma or cholangiocarcinoma. (ascopost.com)
  • One type of cholangiocarcinoma is called a klatskin tumor, named after gerald klatskin. (healthtap.com)
  • Cholangiocarcinoma is considered to be an incurable and rapidly lethal cancer unless both the primary tumor and any metastases can be fully removed by surgery. (wikipedia.org)
  • Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announced today that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) has granted Orphan Drug Designation for melphalan for the treatment of cholangiocarcinoma. (news-medical.net)
  • We are pleased with the receipt of orphan drug designation for melphalan in the treatment of patients with cholangiocarcinoma as it is a key milestone that supports our broader regulatory and development strategy for our Melphalan/Hepatic Delivery System (Melphalan/HDS) as a therapy for primary and metastatic liver cancers,' said Jennifer Simpson, Ph.D., M.S.N., C.R.N.P., President and Chief Executive Officer of Delcath. (news-medical.net)
  • METHODS: In this open label, randomised, phase 3 trial, we randomly assigned patients (in a 1:1 ratio) with metastatic biliary-tract cancer (cholangiocarcinoma, gallbladder cancer, or ampulla of Vater cancer) to receive either first-line treatment with chemotherapy alone (gemcitabine 1000 mg/m(2) on day 1 and oxaliplatin 100 mg/m(2) on day 2) or chemotherapy plus erlotinib (100 mg daily). (uptodate.com)
  • Participants must have unresectable or metastatic histologically or cytologically confirmed intrahepatic cholangiocarcinoma or extrahepatic cholangiocarcinoma (i.e. hilar and distal cholangiocarcinoma). (clinicaltrials.gov)
  • The purpose of this study is evaluate the efficacy of INCB054828 in subjects with advanced/metastatic or surgically unresectable cholangiocarcinoma with FGFR2 translocation who have failed at least 1 previous treatment. (swedish.org)
  • NCT02150967 ) evaluated BGJ398 antitumor activity in patients age ≥ 18 years with advanced or metastatic cholangiocarcinoma containing FGFR2 fusions or other FGFR alterations whose disease had progressed while receiving prior therapy. (nih.gov)
  • Currently, first-line treatment for locally advanced or metastatic cholangiocarcinoma consists of chemotherapy with gemcitabine and cisplatin. (ascopost.com)
  • c Locoregional therapy is for the primary treatment of unresectable and metastatic intrahepatic cholangiocarcinoma only. (oncologynurseadvisor.com)
  • This issue of Surgical Oncology Clinics of North America, edited by Dr. Lawrence Wagman, is devoted to Hepatocellular Cancer, Cholangiocarcinoma, and Metastatic Tumors of the Liver. (indigo.ca)
  • Dr. Marina Baretti from Johns Hopkins University was awarded $60,000 to help support her work on immunotherapy for metastatic cholangiocarcinoma. (einpresswire.com)
  • Hence we explored the role of SBRT in localized non-metastatic hilar or intrahepatic cholangiocarcinoma. (jcancer.org)
  • Cancers arising in the perihilar region, which account for 60 to 70 percent of extrahepatic cholangiocarcinomas, have been further classified according to the pattern of involvement of the hepatic ducts (the Bismuth-Corlette classification) ( figure 2 ) [ 4,5 ]. (uptodate.com)
  • These neoplasms arise from the biliary tract and can be categorized according to their anatomical location as intrahepatic and extrahepatic cholangiocarcinomas. (springer.com)
  • Intrahepatic tumors occur starting in the secondary biliary radicles and distal extrahepatic cholangiocarcinomas arise from the common bile duct forward. (appliedradiology.com)
  • Tumors of this region are also known as extrahepatic cholangiocarcinomas (Figure 2). (oncolink.org)
  • 17 These are interestingly seen more with extrahepatic cholangiocarcinomas and gallbladder cancers as opposed to intrahepatic cholangiocarcinomas. (nature.com)
  • There is much confusion in the literature as to the definition of extrahepatic cholangiocarcinomas, and there is thus some overlap. (radiopaedia.org)
  • More recently, the term cholangiocarcinoma has been used to designate bile duct cancers arising in the intrahepatic, perihilar, or distal (extrahepatic) biliary tree, exclusive of gallbladder and ampulla of Vater ( figure 1 ) [ 1-3 ]. (uptodate.com)
  • Does intrahepatic cholangiocarcinoma have better prognosis compared to perihilar cholangiocarcinoma? (medscape.com)
  • The patient presented with classic imaging findings of a perihilar cholangiocarcinoma. (appliedradiology.com)
  • Cholangiocarcinomas are divided into intrahepatic, extrahepatic (perihilar), and distal extrahepatic cholangiocarcinoma. (appliedradiology.com)
  • The AJCC defines perihilar cholangiocarcinoma (Klatskin tumors) as occurring from the right and left hepatic ducts to the common bile duct. (appliedradiology.com)
  • 7, 8 The most commonly used classification system for perihilar cholangiocarcinomas specifically is the Bismuth-Corlette System. (appliedradiology.com)
  • Tumors of this region are also known as perihilar cholangiocarcinomas or Klatskin tumors. (oncolink.org)
  • Major hepatectomy for perihilar cholangiocarcinoma. (springer.com)
  • Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US Centers. (springer.com)
  • Periductal infiltrating intrahepatic tumors are most common at the hilum (comprise over 70% of hilar-perihilar cholangiocarcinomas), where they are known as Klatskin tumors 3 but can also be seen in combination with mass-forming tumors within the liver. (radiopaedia.org)
  • Evolution of surgical treatment for perihilar cholangiocarcinoma: a single-center 34-year review of 574 consecutive resections. (springermedizin.at)
  • Preoperative endoscopic versus percutaneous transhepatic biliary drainage in potentially resectable perihilar cholangiocarcinoma (DRAINAGE trial): design and rationale of a randomized controlled trial. (springermedizin.at)
  • Cholangiocarcinoma is a group of cancers that begin in the bile ducts. (medlineplus.gov)
  • cholangiocarcinoma begins in the small bile ducts within the liver. (medlineplus.gov)
  • The remaining cases are classified as distal cholangiocarcinomas, which begin in bile ducts outside the liver. (medlineplus.gov)
  • The three types of cholangiocarcinoma do not usually cause any symptoms in their early stages, and this cancer is usually not diagnosed until it has already spread beyond the bile ducts to other tissues. (medlineplus.gov)
  • In Southeast Asia, infection with parasitic worms that live in the human bile ducts greatly increase the risk of developing cholangiocarcinoma. (medlineplus.gov)
  • Cholangiocarcinomas (bile duct cancers) arise from the epithelial cells of the bile ducts. (uptodate.com)
  • Cholangiocarcinoma , also known as bile duct cancer , is a type of cancer that forms in the bile ducts . (wikipedia.org)
  • Risk factors for cholangiocarcinoma include primary sclerosing cholangitis (an inflammatory disease of the bile ducts), ulcerative colitis , cirrhosis , hepatitis C , hepatitis B , infection with certain liver fluke , and some congenital liver malformations. (wikipedia.org)
  • Bile duct carcinoma (cholangiocarcinoma) is a cancer of the bile ducts, the tubes that connect the liver and gall bladder to the small intestine. (medindia.net)
  • Cholangiocarcinomas are tumors that arise in the bile ducts - tubes from the liver to the small intestine that carry bile, a fluid that helps digest fats and excrete wastes. (curetoday.com)
  • Cholangiocarcinomas that occur in the small bile ducts within the liver are termed "intrahepatic. (curetoday.com)
  • Bile duct cancer (cholangiocarcinoma) is a cancer of the biliary duct system, which includes the gallbladder, bile ducts, and certain cells inside the liver. (va.gov)
  • Cholangiocarcinoma is a "silent" form of cancer that originates from the cells lining the bile ducts. (businesswire.com)
  • If approved, pemigatinib would be the first targeted therapy for patients with cholangiocarcinoma, a rare cancer that impacts the bile ducts. (ajmc.com)
  • Cholangiocarcinoma is cancer of the bile ducts. (bostonscientific.com)
  • Herein, we review the topic of EMT in cholangiocarcinoma (CCA), a primary liver cancer arising from the epithelial cells lining the bile ducts (cholangiocytes) and characterized by an abundant stromal reaction. (mdpi.com)
  • Cholangiocarcinoma, cancer of the bile ducts, is a rare cancer that is, unfortunately, associated with a high mortality rate. (heraldtribune.com)
  • In specimens of bile ducts from patients with hepatolithiasis, biliary intraepithelial neoplasia (BilIN) is a common finding and is considered to be a precursor lesion of cholangiocarcinoma. (radiopaedia.org)
  • Intrahepatic cholangiocarcinoma (ICC) is a malignant epithelial neoplasm composed of cells resembling cholangiocytes that line the intrahepatic bile ducts in portal areas of the hepatic lobule. (sigmaaldrich.com)
  • Cholangiocarcinoma refers to cancers that start in your bile ducts . (roswellpark.org)
  • Unfortunately, patients with cholangiocarcinoma often have obstructed bile ducts that limit GI tract functionality and can potentially lead to infections if they have stents or drains in their bile ducts. (roswellpark.org)
  • Cholangiocarcinoma or bile duct cancer is a form of cancer that is composed of mutated epithelial cells (or cells showing characteristics of epithelial differentiation) that originate in the bile ducts. (wikipedia.org)
  • See 'Epidemiology, pathogenesis, and classification of cholangiocarcinoma' and 'Treatment of localized cholangiocarcinoma: Adjuvant and neoadjuvant therapy and prognosis' and 'Treatment options for locally advanced cholangiocarcinoma' and 'Gallbladder cancer: Epidemiology, risk factors, clinical features, and diagnosis' and 'Ampullary carcinoma: Epidemiology, clinical manifestations, diagnosis and staging' . (uptodate.com)
  • Hepatocellular carcinoma (HCC) and hepatic cholangiocarcinoma (CC) are the most aggressive malignancies with a poor prognosis in humans, and hepatic cholangiocarcinoma (CC) exhibits greater malignant behaviour. (springer.com)
  • Clinicopathologic features and prognosis of combined hepatocellular cholangiocarcinoma. (springer.com)
  • Combined hepatocellular and cholangiocarcinoma is a more aggressive malignancy with a poorer prognosis than ordinary hepatocellular carcinoma (HCC). (atlasgeneticsoncology.org)
  • Patients with advanced cholangiocarcinoma face a poor prognosis, and currently there is no standard of care beyond first-line chemotherapy. (ajmc.com)
  • Uenishi T, Hirohashi K, Kubo S, et al: Histologic factors affecting prognosis following hepatectomy for intrahepatic cholangiocarcinoma. (spandidos-publications.com)
  • Clear-cell cholangiocarcinoma is a very uncommon variant of cholangiocarcinoma with a largely unknown natural history and prognosis. (isciii.es)
  • Cholangiocarcinoma is an aggressive malignancy with a poor prognosis, with no effective therapy other than surgical resection. (aacrjournals.org)
  • Prognosis would depend on a number of factors, including whether the cholangiocarcinoma is associated with primary sclerosing cholangitis, the location of the cancer , the, stage of the cancer at diagnosis (e.g. (healthtap.com)
  • Zurück zum Zitat Choi SB, Kim KS, Choi JY, Park SW, Choi JS, Lee WJ et al (2009) The prognosis and survival outcome of intrahepatic cholangiocarcinoma following surgical resection: association of lymph node metastasis and lymph node dissection with survival. (springermedizin.de)
  • Unresectable intrahepatic and hilar cholangiocarcinomas carry a dismal prognosis. (jcancer.org)
  • Liver cancer consists of two main histological subtypes, hepatocellular carcinoma and cholangiocarcinoma, both of which have poor prognosis. (springer.com)
  • In the proper clinical setting, detection of a hypodense hepatic lesion with peripheral enhancement, biliary dilatation, and contrast enhancement on delayed images are highly suggestive of peripheral intrahepatic cholangiocarcinoma. (springer.com)
  • Recognizing a dilated or crowded biliary tree is a critical, though nonspecific, step in the workup of cholangiocarcinomas. (appliedradiology.com)
  • Patients with cholangiocarcinoma most often present with painless jaundice and other signs of biliary obstruction: scleral icterus, dark urine, clay-colored stools, or generalized pruritus. (appliedradiology.com)
  • 129 U/L in the setting of a biliary mass is highly suggestive of cholangiocarcinoma. (appliedradiology.com)
  • Subjects will be adults with cholangiocarcinoma and benign biliary stricture, candidates to receive a first-line systemic therapy, who meet all of the inclusion criteria and none of the exclusion criteria within 28 days prior to the first day of study treatment. (clinicaltrials.gov)
  • Relief of biliary obstruction is the most accepted treatment approach for most patients with cholangiocarcinoma. (clevelandclinic.org)
  • It can be concluded that cholangiocarcinoma remains a possible diagnosis in PJS patients, as in others that present with biliary obstruction. (hindawi.com)
  • Introduction: Due to the perceived difficulty in dissecting hilar cholangiocarcinomas off of the portal structures and in performing complex biliary reconstructions, very few centers have used minimally invasive techniques for these tumors. (sages.org)
  • The management of hilar cholangiocarcinoma has evolved over the past 20 years, with data from large institutional series emerging, which has influenced decisions regarding the need for preoperative biliary drainage, portal-vein embolization, extent of surgical resection, role of transplantation, and efficacy of adjuvant and palliative therapies. (springer.com)
  • Intrahepatic cholangiocarcinoma (iCCA) is a lethal primary liver cancer that exhibits histologic features of the biliary tract and commonly harbors mutations in IDH1/2, BAP1, KRAS, TP53, SMAD4 , and ARID1A ( 1, 2 ). (aacrjournals.org)
  • Hepatolithiasis is an established risk factor for cholangiocarcinoma (CCA), and chronic proliferative inflammation may be involved in biliary carcinogenesis and in inducing the upregulation of cell-proliferating factors. (nih.gov)
  • 1.1 Current evidence on the safety and efficacy of endoscopic bipolar radiofrequency ablation for treating biliary obstructions caused by cholangiocarcinoma or pancreatic adenocarcinoma is inadequate in quantity and quality. (nice.org.uk)
  • Laurent A, Tayar C, Cherqui D. Cholangiocarcinoma: preoperative biliary drainage (Con). (springermedizin.at)
  • Cholangiocarcinoma (CC) worldwide is the most common biliary malignancy with poor prognostic value and new systemic treatments are desirable. (spandidos-publications.com)
  • Cholangiocarcinoma is the term applied to primary malignant tumours of the biliary tract. (taylorfrancis.com)
  • Cholangiocarcinomas, the second most common primary malignancy of the liver, are a heterogeneous group of malignancies ranging from intrahepatic to hilar, distal biliary and ampullary cancers( 1 , 2 ). (jcancer.org)
  • Cholangiocarcinoma, or cancer of the bile duct, is an indication for the Whipple procedure when the cancer is present in the distal biliary system, usually the common bile duct that drains into the duodenum. (wikipedia.org)
  • Hepatectomy has become the standard of care for resectable hilar cholangiocarcinoma, while transplantation can offer promising results for unresectable patients with localized disease. (springer.com)
  • In ClarIDHy, ivosidenib was evaluated in 185 patients with advanced, unresectable IDH1- mutated cholangiocarcinoma who had received one or two prior lines of therapy. (ascopost.com)
  • All patients had advanced unresectable cholangiocarcinoma and IDH1 mutation based on central testing, ECOG performance status 0-1, and measurable disease per RECIST v1.1. (ascopost.com)
  • What are the ways to manage unresectable cholangiocarcinoma? (healthtap.com)
  • Cholangiocarcinoma or cancer of the billiary tract in the liver is a difficult cancer to treat when unresectable. (healthtap.com)
  • Patients with unresectable intrahepatic or hilar cholangiocarcinoma or those with positive margins were included in this study. (jcancer.org)
  • SBRT is an effective and reasonably safe local therapy option for unresectable intrahepatic or hilar cholangiocarcinoma. (jcancer.org)
  • Tumors involving the hepatic duct bifurcation (hilar cholangiocarcinomas) are collectively referred to as Klatskin tumors. (uptodate.com)
  • Combined hepatocellular and cholangiocarcinoma (biphenotypic) tumors: imaging features and diagnostic accuracy of contrast-enhanced CT and MRI. (medscape.com)
  • These tumors are also known as intrahepatic cholangiocarcinomas. (oncolink.org)
  • For one of the rarest and most aggressive of tumors-cholangiocarcinoma-two novel molecularly targeted agents yielded encouraging outcomes in advanced disease in studies reported at the European Society for Medical Oncology (ESMO) Congress 2019. (ascopost.com)
  • The study is focused on tumors that arise in the bile duct epithelium within the liver, meaning they are anatomically classified as intrahepatic cholangiocarcinomas. (onclive.com)
  • Intraductal tumors comprise 8-18% of resected cholangiocarcinomas 3 and a much smaller number of all cholangiocarcinomas (as most are inoperable). (radiopaedia.org)
  • Discussion: Minimally invasive approaches for both intrahepatic and hilar cholangiocarcinomas appear feasible and safe. (sages.org)
  • Global Markets Direct's, 'Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2016', provides an overview of the Bile Duct Cancer (Cholangiocarcinoma) pipeline landscape. (reportsnreports.com)
  • Distal extrahepatic bile duct cancer is also called extrahepatic cholangiocarcinoma. (oncolink.org)
  • The most common technique of a pancreaticoduodenectomy consists of the en bloc removal of the distal segment (antrum) of the stomach, the first and second portions of the duodenum, the head of the pancreas, the common bile duct, and the gallbladder. (wikipedia.org)
  • Patients were divided into hilar cholangiocarcinomas and intrahepatic cholaniocarcinomas. (sages.org)
  • The Bismuth classification was used to stratify the hilar cholangiocarcinomas. (sages.org)
  • Peripheral intrahepatic cholangiocarcinoma and gallbladder cancer will also be considered as closely related conditions that are diagnosed and managed in a similar way to hilar tumours. (taylorfrancis.com)
  • This portion is not done en bloc, as the gallbladder is removed separately. (wikipedia.org)
  • Patients with advanced cholangiocarcinoma with an isocitrate dehydrogenase 1 ( IDH1 ) mutation showed clinical benefit and improved progression-free survival (PFS) when treated with ivosidenib vs placebo, according to results presented by Ghassan K. Abou-Alfa, MD , at the European Society for Medical Oncology (ESMO) Congress 2019 (Abstract LBA10). (ascopost.com)
  • The trial is enrolling patients with mesothelin expressing non-small cell lung cancer (NSCLC), ovarian cancer, cholangiocarcinoma or malignant pleural/peritoneal mesothelioma. (thefreedictionary.com)
  • Malignant hypercalcemia and thrombocytopenia may result from bone metastasis of cholangiocarcinoma (CC). Our case was 53-year-old man admitted to emergency department with symptoms of anorexia, weight loss, nausea, vomiting, and general fatigue in February 2012. (hindawi.com)
  • Cholangiocarcinoma (CCA) is a malignant neoplasm affecting thousands of individuals worldwide. (spandidos-publications.com)
  • Our study shows that HGF activates both proliferation and invasion machinery in cholangiocarcinoma cells, suggesting that HGF might promote their malignant behavior by concomitant activation of different biological functions. (aacrjournals.org)
  • Most cholangiocarcinoma staging systems use a numerical scale ranging from 1 through 4, with higher numbers corresponding to more advanced cancers. (moffitt.org)
  • Intrahepatic bile duct cancers are also called intrahepatic cholangiocarcinomas. (oncolink.org)
  • Like other cancers, cholangiocarcinoma is staged from I-IV. (restonhospital.com)
  • Interpretation of the available, limited data that exists suggests a small survival advantage of chemotherapy and radiation for cholangiocarcinoma. (clevelandclinic.org)
  • Conclusion BGJ398 is a first-in-class FGFR kinase inhibitor with manageable toxicities that shows meaningful clinical activity against chemotherapy-refractory cholangiocarcinoma containing FGFR2 fusions. (nih.gov)
  • This study evaluates the genomic, epigenetic, and pharmacologic landscapes of intrahepatic cholangiocarcinoma, which is both molecularly heterogeneous and resistant to chemotherapy. (onclive.com)
  • Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma ", Hepatology, 2014, 59, 1427-1434. (thefreedictionary.com)
  • Why choose Johns Hopkins Division of Gastroenterology and Hepatology for cholangiocarcinoma? (hopkinsmedicine.org)
  • In a study recently published in Hepatology from the Andersen Group at Biotech Research and Innovation Center, it was shown that using a single-gene dissection approach in patients with intrahepatic cholangiocarcinoma can characterize divergent cancer programs and drug vulnerabilities. (onclive.com)
  • A phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor (TKI), in patients with previously-treated advanced cholangiocarcinoma containing FGFR2 fusions. (onclive.com)
  • Fibroblast growth factor receptor 2 ( FGFR2) fusions/translocations are present in 13% to 17% of intrahepatic cholangiocarcinomas. (nih.gov)
  • The selective pan-FGFR kinase inhibitor infigratinib (BGJ398) showed meaningful antitumor activity and a manageable safety profile in patients with previously treated intrahepatic cholangiocarcinoma (IHC) who harbor FGFR2 fusions, according to updated phase II findings presented at the 2018 ESMO Congress. (onclive.com)
  • We are excited to share updated data for pemigatinib, which may provide a promising and targeted treatment approach for patients with cholangiocarcinoma harboring FGFR2 fusions or rearrangements," said Peter Langmuir, MD, group vice president, targeted therapies, Incyte, in a statement. (ajmc.com)
  • The primary objective of this study is to estimate the frequency of FGFR2 fusions in archived intrahepatic cholangiocarcinoma (iCCA) or mixed hepatocellular-cholangiocarcinoma (HCC-CCA) tu. (bioportfolio.com)
  • Bardeesy presented the information during the 2018 Cholangiocarcinoma Foundation Annual Conference, held Jan. 31 through Feb. 2 in Salt Lake City. (curetoday.com)
  • SALT LAKE CITY, UT, USA, August 3, 2018 / EINPresswire.com / -- The Cholangiocarcinoma Foundation recently announced a first of its kind $60,000 collaborative Young Investigator Award with three partner organizations, AMMF - The Cholangiocarcinoma Charity (UK), The Bili Project Foundation, and Target Cancer Foundation. (einpresswire.com)
  • Combined vascular resection in operative resection for hilar cholangiocarcinoma: does it work or not? (springer.com)
  • Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. (springer.com)
  • Factors influencing postoperative morbidity, mortality, and survival after resection for hilar cholangiocarcinoma. (springermedizin.at)
  • Preoperative cholangitis and future liver remnant volume determine the risk of liver failure in patients undergoing resection for hilar cholangiocarcinoma. (springermedizin.at)
  • To evaluate the median progression free survival (PFS) of cabozantinib in patients with advanced cholangiocarcinoma after progression on 1 or 2 prior systemic therapies. (clinicaltrials.gov)
  • According to the authors, ivosidenib provided significant improvement in PFS and a trend towards favorable overall survival compared to placebo in patients with advanced cholangiocarcinoma and an IDH1 mutation. (ascopost.com)
  • Implications of CA19-9 elevation for survival, staging, and treatment sequencing in intrahepatic cholangiocarcinoma: A national cohort analysis. (medscape.com)
  • While this information is an important consideration in planning a patient's treatment, cholangiocarcinoma staging is too general to reliably predict any patient's outcome. (moffitt.org)
  • As part of the cholangiocarcinoma staging process at Moffitt Cancer Center, each patient is thoroughly evaluated by a multispecialty team of bile duct cancer experts, including surgeons, oncologists and other medical professionals. (moffitt.org)
  • If you'd like to learn more about cholangiocarcinoma staging, the bile cancer experts at Moffitt can explain the statistics and put this information into perspective for you. (moffitt.org)
  • Staging of intrahepatic cholangiocarcinoma. (medscape.com)
  • This book contains an up-to-date review of diagnostic and staging tools of cholangiocarcinoma, and of long-term outcome of surgery and liver transplantation. (springer.com)
  • Positron emission tomography/CT (PET/CT) is useful in staging and identify metastasis in intrahepatic cholangiocarcinoma. (appliedradiology.com)
  • Jarnagin WR, Fong Y and DeMatteo RP: Staging, resectability and outcome in 225 patients with hilar cholangiocarcinoma. (spandidos-publications.com)
  • Staging depends on the growth pattern/type of cholangiocarcinoma. (radiopaedia.org)
  • Staging, resectability and outcome in 225 patients with hilar cholangiocarcinoma. (springermedizin.at)
  • The purpose of our study was to evaluate the imaging features and patterns of contrast enhancement in peripheral cholangiocarcinomas with computed tomography (CT) and correlate these features with histologic findings when available. (springer.com)
  • We reviewed the CT scans of 24 patients with 25 peripheral cholangiocarcinomas proved by orthotopic liver transplantation ( n = 1), liver resection ( n = 7), percutaneous needle biopsy ( n = 10), and fine needle aspiration biopsy ( n = 6). (springer.com)
  • Intrahepatic cholangiocarcinomas can originate from either small intrahepatic ductules (peripheral cholangiocarcinomas) or large intrahepatic ducts proximal to the bifurcation of the right and left hepatic ducts. (uptodate.com)
  • Hepatocellular carcinoma and intrahepatic peripheral cholangiocarcinoma: enhancement patterns with quadruple phase helical CT--a comparative study. (medscape.com)
  • Yeh CN, Yeh TS, Chen TC, Jan YY and Chen MF: Gross pathological classification of peripheral cholangiocarcinoma determines the efficacy of hepatectomy. (spandidos-publications.com)
  • Chen MF: Peripheral cholangiocarcinoma (cholangiocellular carcinoma): clinical features, diagnosis and treatment. (spandidos-publications.com)
  • Singal AK, Vauthey JN, Grady JJ, Stroehlein JR. Intra-hepatic cholangiocarcinoma--frequency and demographic patterns: thirty-year data from the M.D. Anderson Cancer Center. (medscape.com)
  • They tend to be well delineated but irregular in outline and are often associated with capsular retraction 2 , which if present is helpful in distinguishing cholangiocarcinomas from other hepatic tumours . (radiopaedia.org)
  • Aggressive surgical approaches to hilar cholangiocarcinoma: hepatic or local resection? (springermedizin.at)
  • Kosuge T, Yamamoto J, Shimada K, Yamasaki S, Makuuchi M. Improved surgical results for hilar cholangiocarcinoma with procedures including major hepatic resection. (springermedizin.at)
  • See 'Epidemiology, pathogenesis, and classification of cholangiocarcinoma' . (uptodate.com)
  • Establish ground-level truth on cholangiocarcinoma epidemiology to help drive additional research and therapies. (businesswire.com)
  • Shaib Y and El-Serag HB: The epidemiology of cholangiocarcinoma. (spandidos-publications.com)
  • Histologically or cytologically confirmed cholangiocarcinoma. (swedish.org)
  • Subjects are required to have a histologically-confirmed diagnosis of IDH1 gene-mutated cholangiocarcinoma that is not eligible for curative resection, transplantation, or ablative therapies prior to enrollment.IDH1 mutation testing will be performed at participating investigative sites. (clinicaltrials.gov)
  • Histologically, cholangiocarcinomas are divided into well, moderately and poorly differentiated adenocarcinomas 2 . (radiopaedia.org)
  • Cholangiocarcinoma screening cannot be performed with any degree of reliability in individuals who are not experiencing symptoms. (moffitt.org)
  • For these reasons, cholangiocarcinoma is usually found only after the cancer has advanced enough to cause symptoms. (moffitt.org)
  • In the absence of cholangiocarcinoma screening tests, individuals are urged to pay close attention to potential signs of bile duct problems, the most common of which are jaundice (a yellowing of the skin and eyes) and abdominal pain, and to promptly report those symptoms to a physician. (moffitt.org)
  • [2] Symptoms of cholangiocarcinoma may include abdominal pain , yellowish skin , weight loss , generalized itching , and fever. (wikipedia.org)
  • Cholangiocarcinoma is usually in an advanced stage by the time any signs or symptoms develop. (knowcancer.com)
  • Cholangiocarcinomas are sometimes misdiagnosed due to a lack of unique symptoms and no specific screening tests. (roswellpark.org)
  • Patel T: Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. (spandidos-publications.com)
  • Update on the Diagnosis and Treatment of Cholangiocarcinoma. (medscape.com)
  • There is currently no clear national consensus for the optimal diagnosis and treatment of cholangiocarcinoma. (bmj.com)
  • Currently NHS England does not routinely fund this treatment for cholangiocarcinoma , based on clinical advice that there is not yet sufficient evidence of its effectiveness compared to other treatments available. (thefreedictionary.com)
  • The clinical manifestations and diagnosis of cholangiocarcinoma will be reviewed here. (uptodate.com)
  • Intrahepatic and extrahepatic types of cholangiocarcinoma differ significantly in clinical presentation and underlying genetic aberrations. (nature.com)
  • New data from two clinical trials presented at the International Liver Congress 2013 demonstrated substantial improvements in the detection of both HCC and cholangiocarcinoma using diagnostic urine tests. (oncologynurseadvisor.com)
  • DLEC1 methylation is associated with a better clinical outcome in patients with intrahepatic cholangiocarcinoma of the small duct subtype. (bioportfolio.com)
  • A significant improvement in progression-free survival, by central review, and a favorable overall survival trend and tolerable safety profile all support the clinical benefit of ivosidenib in patients with IDH1 -mutated advanced cholangiocarcinoma," Dr. Abou-Alfa said during a press briefing. (ascopost.com)
  • Whereas the therapeutic options have improved for many other diseases, the clinical opportunities for most patients diagnosed with cholangiocarcinoma are limited-this is a dismal disease. (onclive.com)
  • Cholangiocarcinoma (CCA) is an extremely aggressive cancer that is usually fatal. (nih.gov)
  • Aspirin's anti-inflammatory action is protective against another aggressive cancer: cholangiocarcinoma. (oncologynurseadvisor.com)
  • Cholangiocarcinoma is a particularly aggressive form of cancer, and fatal in almost all cases. (knowcancer.com)
  • in particular intrahepatic cholangiocarcinoma now accounts for more deaths than hepatoma in the Western countries.2 Cholangiocarcinoma has the potential to be diagnosed early, when it is small, localised, and amenable to an aggressive treatment approach. (taylorfrancis.com)
  • Surgical treatment of hilar cholangiocarcinoma in the new era: the Asan experience. (springer.com)
  • As a second step, the study will evaluate the prognostic and predictive value of cholangiocarcinoma exosomes levels in plasma in a prospectively recruited cohort of cholangiocarcinoma patients before and after surgical resection. (clinicaltrials.gov)
  • Liver transplantation is currently an effective method of treatment for cholangiocarcinoma of the hilum of the liver in patient who cannot undergo surgical resection. (clevelandclinic.org)
  • To provide a comprehensive review of the preoperative and operative considerations for the surgical management of hilar cholangiocarcinoma. (springer.com)
  • Surgical resection remains the only proven curative treatment for peri-hilar cholangiocarcinoma. (springermedizin.at)
  • Zurück zum Zitat Konstadoulakis MM, Roayaie S, Gomatos IP, Labow D, Fiel MI, Miller CM et al (2008) Fifteen-year, single-center experience with the surgical management of intrahepatic cholangiocarcinoma: operative results and long-term outcome. (springermedizin.de)
  • Depending on the location and extension of the cholangiocarcinoma, curative surgical resection may require hepatectomy, or removal of part of the liver, with or without pancreaticoduodenectomy. (wikipedia.org)
  • Our main aims are to raise the awareness of cholangiocarcinoma (bile duct cancer), to provide information, and to support specialised research teams in their work to find the causes, methods of earlier diagnosis and treatments for this disease. (justgiving.com)
  • Cholangiocarcinoma is recognized by the FDA as an orphan disease, usually defined as a condition that affects fewer than 200,000 people nationwide. (news-medical.net)
  • A new understanding of the genetic mutations that drive the rare and difficult-to-treat cancer cholangiocarcinoma, along with the testing of targeted drugs and immunotherapies in people with the disease, are laying the groundwork for long-awaited advances in therapy. (curetoday.com)
  • Cholangiocarcinoma is a heterogeneous and target-rich disease with differences in actionable targets. (nature.com)
  • The agreement allows the Cholangiocarcinoma Foundation to access previously inaccessible information, data, and disease-treatment reference points through Komodo Health's largest, most actionable healthcare map in the U.S. (businesswire.com)
  • Non-alcoholic fatty liver disease as a risk factor for cholangiocarcinoma: a systematic review and meta-analysis. (springer.com)
  • Intrahepatic cholangiocarcinoma is a complex disease with three different histologic subtypes, the large duct, small duct, and bile ductular types. (bioportfolio.com)
  • For these reasons, screening is not currently recommended for people at average risk, although it may be considered in people at high risk, such as people with primary sclerosing cholangitis, a chronic liver disease that puts people at high risk for cholangiocarcinoma. (heraldtribune.com)
  • The appropriate stratification of patients with intrahepatic cholangiocarcinoma comes with implications for the development of precision medicine in this disease, Andersen adds. (onclive.com)
  • To analyse the results and prognostic factors affecting disease-free and overall survival following potentially curative resection for intrahepatic cholangiocarcinoma (IHCC). (ovid.com)
  • As a rare and lethal disease, cholangiocarcinoma lacks attention and sufficient resources. (einpresswire.com)
  • There is a vast, unmet need for education about cholangiocarcinoma across the entire disease spectrum-from bench to bedside. (einpresswire.com)
  • Somatic mutations in many different genes have been found in cholangiocarcinoma. (medlineplus.gov)
  • Overexpression of c-Met has frequently been found in cholangiocarcinoma especially of well-differentiated type suggesting the role of c-Met in cholangiocarcinogenesis. (aacrjournals.org)
  • Intrahepatic cholangiocarcinoma (ICC) is a fatal primary liver cancer (PLC) that affects 5-10% of all PLCs. (nih.gov)
  • Intrahepatic cholangiocarcinoma (iCCA) is a primary liver cancer epidemiologically linked with liver injury, which has poorly understood incipient stages and lacks early diagnostics and effective therapies. (aacrjournals.org)
  • In a case series from Mount Sinai Beth Israel Medical Center, survival of these patients appears to be better than survival for either liver cancer or cholangiocarcinoma. (ascopost.com)
  • Researchers have also investigated inherited variations in several genes as possible risk factors for cholangiocarcinoma. (medlineplus.gov)
  • Several non-genetic risk factors for cholangiocarcinoma have been identified. (medlineplus.gov)
  • Although most people present without any known risk factors evident, a number of risk factors for the development of cholangiocarcinoma have been described. (wikipedia.org)
  • Other risk factors for cholangiocarcinoma are mostly beyond a person's control: other liver diseases, parasites and genetic conditions. (heraldtribune.com)
  • A meta-analysis of risk factors for intrahepatic cholangiocarcinoma. (springer.com)